AAV-mediated delivery of therapeutic antibodies to inner ear

By introducing polypeptide sequences encoding antibodies or antigen-binding antibody fragments using AAV vectors, the treatment difficulties of mammalian inner ear disorders, especially sensorineural hearing loss, and effective regulation of VEGF activity and treatment of inner ear disorders are achieved.

CN119055798APending Publication Date: 2024-12-03AKOUOS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411199182.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-12-19
Filing Date
2018-12-19
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat inner ear disorders in mammals, especially sensorineural hearing loss, and the existing methods have limited effect on the regulation of VEGF activity.

Method used

Adeno-associated virus (AAV) vector is used to introduce polypeptide sequences encoding antibodies or antigen-binding antibody fragments into the mammalian inner ear to reduce VEGF activity or increase antibody levels by specific binding, thereby treating inner ear disorders.

Benefits of technology

The level of antibody or antigen-binding antibody fragments is achieved in the mammalian inner ear and the VEGF activity is reduced, thereby treating inner ear diseases such as acoustic neuroma, vestibular schwannoma or type 2 neurofibromatosis, improving the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055798A_ABST
    Figure CN119055798A_ABST
Patent Text Reader

Abstract

Provided herein are methods comprising introducing a therapeutically effective amount of an adeno-associated virus (AAV) vector into the inner ear of a mammal, the AAV vector comprises a nucleotide sequence encoding the following polypeptides: (a) a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide comprising an antigen binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to the signal peptide.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of an invention patent application with an application date of December 19, 2018, a priority date of December 19, 2017, an application number of 201880086702.2, and an invention name of “AAV-mediated delivery of therapeutic antibodies to the inner ear”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims priority to U.S. Provisional Patent Application Serial No. 62 / 607,665, filed on December 19, 2017, the entire contents of which are incorporated herein by reference. Technical Field

[0004] The present disclosure generally relates to the use of nucleic acids to treat hearing loss in human subjects. Background of the Invention

[0006] Sensorineural hearing loss is hearing loss caused by malfunction of cells (e.g., hair cells) in the inner ear of mammals. Non-limiting causes of sensorineural hearing loss include exposure to loud noise, head trauma, viral infection, autoimmune inner ear disease, hereditary hearing loss, aging, inner ear malformations, Meniere's disease, otosclerosis, and tumors. Summary of the invention

[0007] The present invention relates to a method comprising introducing a therapeutically effective amount of any adeno-associated virus (AAV) vector into the inner ear of a mammal (e.g., a human), wherein the AAV vector comprises a nucleotide sequence encoding the following polypeptides: (a) a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide; or (b) a polypeptide comprising an antigen-binding antibody fragment operably linked to a signal peptide.

[0008] Provided herein are methods for increasing the level of antibodies or antigen-binding antibody fragments in the inner ear of a mammal in need thereof, the method comprising: introducing a therapeutically effective amount of an AAV vector into the inner ear of the mammal, the AAV vector comprising a nucleotide sequence encoding the following polypeptides: (a) a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide; or (b) a polypeptide comprising an antigen-binding antibody fragment linked to a signal peptide; wherein the introduction results in an increase in the level of the antibody or antigen-binding antibody fragment in the inner ear of the mammal.

[0009] In some embodiments, the antibody or antigen-binding antibody fragment specifically binds to vascular endothelial growth factor (VEGF). In some embodiments, the antibody or antigen-binding antibody fragment reduces VEGF activity. In some embodiments of any of the methods described herein, the AAV vector further comprises one or both of a promoter and a Kozak sequence operably linked to the sequence encoding the antibody or antigen-binding antibody fragment.

[0010] In some embodiments, the AAV vector comprises a promoter selected from the group consisting of an inducible promoter, a constitutive promoter, and a tissue-specific promoter. In some embodiments of any of the methods described herein, the AAV vector further comprises a polyadenylation signal sequence.

[0011] In some embodiments of any of the methods described herein, the mammal is a human. In some embodiments of any of the methods described herein, the mammal has been identified as having an inner ear disorder. In some embodiments of any of the methods described herein, the mammal has been diagnosed as having an inner ear disorder.

[0012] In some embodiments of any of the methods described herein, the AAV vector comprises a nucleic acid sequence encoding a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide.

[0013] In some embodiments of any of the methods described herein, the AAV vector includes a nucleic acid sequence encoding a polypeptide comprising an antigen-binding antibody fragment operably linked to a signal.

[0014] Also provided herein is a method for treating an inner ear disorder in a mammal in need thereof, the method comprising: introducing into the inner ear of the mammal a therapeutically effective amount of an AAV vector, the AAV vector comprising a nucleotide sequence encoding: (a) a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide; or (b) a polypeptide comprising an antigen-binding antibody fragment linked to a signal peptide; wherein the introduction results in the treatment of the inner ear disorder in the mammal.

[0015] In some embodiments of any of the methods described herein, the AAV vector further comprises one or both of a promoter and a Kozak sequence operably linked to the sequence encoding the antibody or antigen-binding antibody fragment.

[0016] In some embodiments, the AAV vector comprises a promoter selected from the group consisting of an inducible promoter, a constitutive promoter, and a tissue-specific promoter.

[0017] In some embodiments of any of the methods described herein, the AAV vector further comprises a polyadenylation signal sequence.

[0018] In some embodiments of any of the methods described herein, the mammal is a human. In some embodiments of any of the methods described herein, the mammal has been identified as having an inner ear disorder. In some embodiments of any of the methods described herein, the mammal has been diagnosed as having an inner ear disorder.

[0019] In some embodiments of any of the methods described herein, the AAV vector comprises a nucleic acid sequence encoding a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide.

[0020] In some embodiments of any of the methods described herein, the AAV vector includes a nucleic acid sequence encoding a polypeptide comprising an antigen-binding antibody fragment operably linked to a signal.

[0021] Also provided herein is a method for reducing VEGF activity in the inner ear of a mammal in need thereof, the method comprising: introducing a therapeutically effective amount of an AAV vector into the inner ear of the mammal, the AAV vector comprising a nucleotide sequence encoding the following polypeptides: (a) a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide; or (b) a polypeptide comprising an antigen-binding antibody fragment linked to a signal peptide; wherein the polypeptide of (a) encodes an antibody that specifically binds to VEGF and reduces VEGF activity, and the polypeptide of (b) encodes an antigen-binding antibody fragment that specifically binds to VEGF and reduces VEGF activity; wherein the introduction reduces VEGF activity in the inner ear of the mammal.

[0022] In some embodiments of any of the methods described herein, the AAV vector further comprises one or both of a promoter and a Kozak sequence operably linked to the sequence encoding the antibody or antigen-binding antibody fragment.

[0023] In some embodiments, the AAV vector comprises a promoter selected from the group consisting of an inducible promoter, a constitutive promoter, and a tissue-specific promoter.

[0024] In some embodiments of any of the methods described herein, the AAV vector further comprises a polyadenylation signal sequence. In some embodiments of any of the methods described herein, the mammal is a human.

[0025] In some embodiments of any of the methods described herein, the mammal has been identified or diagnosed as having an acoustic neuroma. In some embodiments, the mammal has been identified or diagnosed as having a vestibular schwannoma. In some embodiments of any of the methods described herein, the mammal has been identified or diagnosed as having neurofibromatosis type 2.

[0026] In some embodiments of any of the methods described herein, the AAV vector comprises a nucleic acid sequence encoding a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide.

[0027] In some embodiments of any of the methods described herein, the AAV vector comprises a nucleic acid sequence encoding a polypeptide comprising an antigen-binding antibody fragment operably linked to a signal peptide.

[0028] The present invention also provides a method for treating an acoustic neuroma, a vestibular schwannoma or neurofibromatosis type 2 in the inner ear of a mammal, the method comprising: introducing a therapeutically effective amount of an AAV vector into the inner ear of a mammal, the AAV vector comprising a nucleotide sequence encoding the following polypeptides: (a) a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide; or (b) a polypeptide comprising an antigen-binding antibody fragment linked to a signal peptide; wherein the polypeptide of (a) encodes an antibody that specifically binds to VEGF and reduces VEGF activity, and the polypeptide of (b) encodes an antigen-binding antibody fragment that specifically binds to VEGF and reduces VEGF activity; wherein the introduction allows the acoustic neuroma, vestibular schwannoma or neurofibromatosis type II in the inner ear of the mammal to be treated, respectively.

[0029] In some embodiments of any of the methods described herein, the AAV vector further comprises one or both of a promoter and a Kozak sequence operably linked to the sequence encoding the antibody or antigen-binding antibody fragment.

[0030] In some embodiments of any of the methods described herein, the AAV vector comprises a promoter selected from the group consisting of an inducible promoter, a constitutive promoter, and a tissue-specific promoter.

[0031] In some embodiments of any of the methods described herein, the AAV vector further comprises a polyadenylation signal sequence.

[0032] In some embodiments of any of the methods described herein, the mammal is a human. In some embodiments of any of the methods described herein, the mammal has been identified or diagnosed as having an acoustic neuroma. In some embodiments of any of the methods described herein, the mammal has been identified or diagnosed as having a vestibular schwannoma. In some embodiments of any of the methods described herein, the mammal has been identified or diagnosed as having neurofibromatosis type 2.

[0033] In some embodiments of any of the methods described herein, the AAV vector comprises a nucleic acid sequence encoding a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide.

[0034] In some embodiments of any of the methods described herein, the AAV vector comprises a nucleic acid sequence encoding a polypeptide comprising an antigen-binding antibody fragment operably linked to a signal peptide.

[0035] In some embodiments of any of the methods described herein, the antibody comprises an Fc region comprising one or more amino acid substitutions that reduce the half-life of the antibody in a mammal compared to a control antibody; or

[0036] The antigen-binding antibody fragment of the antibody has a reduced in vivo half-life compared to a control antigen-binding antibody fragment.

[0037] Also provided herein is a method comprising introducing into the inner ear of a mammal a therapeutically effective amount of an adeno-associated viral (AAV) vector comprising a nucleotide sequence encoding a soluble vascular endothelial growth factor (VEGF) receptor operably linked to a signal peptide.

[0038] Also provided herein is a method for increasing the level of soluble vascular endothelial growth factor (VEGF) receptor in the inner ear of a mammal in need thereof, the method comprising: introducing a therapeutically effective amount of an AAV vector into the inner ear of the mammal, the AAV vector comprising a nucleotide sequence encoding a soluble VEGF receptor operably linked to a signal peptide; wherein the introduction results in an increase in the level of soluble VEGF receptor in the inner ear of the mammal.

[0039] In some embodiments of any of the methods described herein, the soluble VEGF receptor comprises a portion of the extracellular region of VEGF receptor-1 (VEGFR-1). In some embodiments of any of the methods described herein, a portion of the extracellular region of VEGFR-1 comprises a continuous sequence from wild-type human VEGFR-1. In some embodiments of any of the methods described herein, a portion of the extracellular region of VEGFR-1 comprises one or more immunoglobulin-like domains in the extracellular region from wild-type human VEGFR-1. In some embodiments of any of the methods described herein, a portion of the extracellular region of VEGFR-1 comprises a sequence that is at least 90% identical to a continuous sequence from wild-type human VEGFR-1.

[0040] In some embodiments of any of the methods described herein, the soluble VEGF receptor comprises a portion of the extracellular region of VEGF receptor-2 (VEGFR-2). In some embodiments of any of the methods described herein, a portion of the extracellular region of VEGFR-2 comprises a continuous sequence from wild-type human VEGFR-2. In some embodiments of any of the methods described herein, a portion of the extracellular region of VEGFR-2 comprises one or more immunoglobulin-like domains in the extracellular region from wild-type human VEGFR-2. In some embodiments of any of the methods described herein, a portion of the extracellular region of VEGFR-2 comprises a sequence that is at least 90% identical to a continuous sequence from wild-type human VEGFR-2.

[0041] In some embodiments of any of the methods described herein, the soluble VEGF receptor includes a portion of the extracellular region of VEGFR-1 and a portion of the extracellular region of VEGFR-2. In some embodiments of any of the methods described herein, a portion of the extracellular region of VEGFR-1 includes one or more immunoglobulin-like domains from the extracellular region of wild-type human VEGFR-1; and a portion of the extracellular region of VEGFR-2 includes one or more immunoglobulin-like domains from the extracellular region of wild-type human VEGFR-2. In some embodiments of any of the methods described herein, the soluble VEGF receptor is aflibercept.

[0042] In some embodiments of any of the methods described herein, the soluble VEGF receptor comprises a portion of the extracellular region of VEGF receptor-3 (VEGFR-3). In some embodiments of any of the methods described herein, a portion of the extracellular region of VEGFR-3 comprises a continuous sequence from wild-type human VEGFR-3. In some embodiments of any of the methods described herein, a portion of the extracellular region of VEGFR-3 comprises one or more immunoglobulin-like domains in the extracellular region from wild-type human VEGFR-3. In some embodiments of any of the methods described herein, a portion of the extracellular region of VEGFR-3 comprises a sequence that is at least 90% identical to a continuous sequence from wild-type human VEGFR-3. In some embodiments of any of the methods described herein, the soluble VEGF receptor comprises an Fc domain. In some embodiments of any of the methods described herein, the Fc domain is an IgG1 Fc domain. In some embodiments of any of the methods described herein, the IgG1 Fc domain is a human wild-type IgG1 Fc domain.

[0043] In some embodiments of any of the methods described herein, the soluble VEGF receptor reduces the ability of VEGF to bind to one or more of VEGFR-1, VEGFR-2, and VEGFR-3.

[0044] In some embodiments of any of the methods described herein, the AAV vector further comprises one or both of a promoter and a Kozak sequence operably linked to a sequence encoding a soluble VEGF receptor. In some embodiments of any of the methods described herein, the AAV vector comprises a promoter selected from the group consisting of an inducible promoter, a constitutive promoter, and a tissue-specific promoter. In some embodiments of any of the methods described herein, the AAV vector further comprises a polyadenylation signal sequence.

[0045] In some embodiments of any of the methods described herein, the mammal is a human. In some embodiments of any of the methods described herein, the mammal has been identified as having an inner ear disorder. In some embodiments of any of the methods described herein, the mammal has been diagnosed as having an inner ear disorder.

[0046] Also provided herein is a method for treating an inner ear disorder in a mammal in need thereof, the method comprising: introducing a therapeutically effective amount of an AAV vector into the inner ear of the mammal, the AAV vector comprising a nucleotide sequence encoding a soluble vascular endothelial growth factor (VEGF) receptor operably linked to a signal peptide; wherein the introduction results in the inner ear disorder being treated in the mammal.

[0047] In some embodiments of any of the methods described herein, the AAV vector further comprises one or both of a promoter and a Kozak sequence operably linked to a sequence encoding a soluble VEGF receptor. In some embodiments of any of the methods described herein, the AAV vector comprises a promoter selected from the group consisting of an inducible promoter, a constitutive promoter, and a tissue-specific promoter. In some embodiments of any of the methods described herein, the AAV vector further comprises a polyadenylation signal sequence.

[0048] In some embodiments of any of the methods described herein, the mammal is a human. In some embodiments of any of the methods described herein, the mammal has been identified as having an inner ear disorder. In some embodiments of any of the methods described herein, the mammal has been diagnosed as having an inner ear disorder.

[0049] Also provided herein is a method for reducing VEGF activity in the inner ear of a mammal in need thereof, the method comprising: introducing a therapeutically effective amount of an AAV vector into the inner ear of the mammal, the AAV vector comprising a nucleotide sequence encoding a soluble vascular endothelial growth factor (VEGF) receptor operably linked to a signal peptide; wherein the introduction results in reduced VEGF activity in the inner ear of the mammal.

[0050] In some embodiments of any of the methods described herein, the AAV vector further comprises one or both of a promoter and a Kozak sequence operably linked to a sequence encoding a soluble VEGF receptor. In some embodiments of any of the methods described herein, the AAV vector comprises a promoter selected from the group consisting of an inducible promoter, a constitutive promoter, and a tissue-specific promoter. In some embodiments of any of the methods described herein, the AAV vector further comprises a polyadenylation signal sequence.

[0051] In some embodiments of any of the methods described herein, the mammal is a human. In some embodiments of any of the methods described herein, the mammal has been identified or diagnosed as having an acoustic neuroma. In some embodiments of any of the methods described herein, the mammal has been identified or diagnosed as having a vestibular schwannoma. In some embodiments of any of the methods described herein, the mammal has been identified or diagnosed as having neurofibromatosis type 2.

[0052] The present invention also provides a method for treating an acoustic neuroma, a vestibular schwannoma or neurofibromatosis type 2 in the inner ear of a mammal, the method comprising: introducing a therapeutically effective amount of an AAV vector into the inner ear of the mammal, the AAV vector comprising a nucleotide sequence encoding a soluble vascular endothelial growth factor (VEGF) receptor operably linked to a signal peptide; wherein the introduction results in the treatment of an acoustic neuroma, a vestibular schwannoma or neurofibromatosis type II in the inner ear of the mammal, respectively.

[0053] In some embodiments of any of the methods described herein, the AAV vector further comprises one or both of a promoter and a Kozak sequence operably linked to a sequence encoding a soluble VEGF receptor. In some embodiments of any of the methods described herein, the AAV vector comprises a promoter selected from the group consisting of an inducible promoter, a constitutive promoter, and a tissue-specific promoter. In some embodiments of any of the methods described herein, the AAV vector further comprises a polyadenylation signal sequence.

[0054] In some embodiments of any of the methods described herein, the mammal is a human. In some embodiments of any of the methods described herein, the mammal has been identified or diagnosed as having an acoustic neuroma. In some embodiments of any of the methods described herein, the mammal has been identified or diagnosed as having a vestibular schwannoma. In some embodiments of any of the methods described herein, the mammal has been identified or diagnosed as having neurofibromatosis type 2.

[0055] In some embodiments of any of the methods described herein, the soluble VEGF receptor comprises a portion of the extracellular region of VEGF receptor-1 (VEGFR-1). In some embodiments of any of the methods described herein, a portion of the extracellular region of VEGFR-1 comprises a continuous sequence from wild-type human VEGFR-1. In some embodiments of any of the methods described herein, a portion of the extracellular region of VEGFR-1 comprises one or more immunoglobulin-like domains in the extracellular region from wild-type human VEGFR-1. In some embodiments of any of the methods described herein, a portion of the extracellular region of VEGFR-1 comprises a sequence that is at least 90% identical to a continuous sequence from wild-type human VEGFR-1.

[0056] In some embodiments of any of the methods described herein, the soluble VEGF receptor comprises a portion of the extracellular region of VEGF receptor-2 (VEGFR-2). In some embodiments of any of the methods described herein, a portion of the extracellular region of VEGFR-2 comprises a continuous sequence from wild-type human VEGFR-2. In some embodiments of any of the methods described herein, a portion of the extracellular region of VEGFR-2 comprises one or more immunoglobulin-like domains in the extracellular region from wild-type human VEGFR-2. In some embodiments of any of the methods described herein, a portion of the extracellular region of VEGFR-2 comprises a sequence that is at least 90% identical to a continuous sequence from wild-type human VEGFR-2.

[0057] In some embodiments of any of the methods described herein, the soluble VEGF receptor includes a portion of the extracellular region of VEGFR-1 and a portion of the extracellular region of VEGFR-2. In some embodiments of any of the methods described herein, a portion of the extracellular region of VEGFR-1 includes one or more immunoglobulin-like domains from the extracellular region of wild-type human VEGFR-1; and a portion of the extracellular region of VEGFR-2 includes one or more immunoglobulin-like domains from the extracellular region of wild-type human VEGFR-2. In some embodiments of any of the methods described herein, the soluble VEGF receptor is aflibercept.

[0058] In some embodiments of any of the methods described herein, the soluble VEGF receptor comprises a portion of the extracellular region of VEGF receptor-3 (VEGFR-3). In some embodiments of any of the methods described herein, a portion of the extracellular region of VEGFR-3 comprises a continuous sequence from wild-type human VEGFR-3. In some embodiments of any of the methods described herein, a portion of the extracellular region of VEGFR-3 comprises one or more immunoglobulin-like domains in the extracellular region from wild-type human VEGFR-3. In some embodiments of any of the methods described herein, a portion of the extracellular region of VEGFR-3 comprises a sequence that is at least 90% identical to a continuous sequence from wild-type human VEGFR-3.

[0059] In some embodiments of any of the methods described herein, the soluble VEGF receptor includes an Fc domain. In some embodiments of any of the methods described herein, the Fc domain is an IgG1 Fc domain. In some embodiments of any of the methods described herein, the IgG1 Fc domain is a human wild-type IgG1 Fc domain.

[0060] In some embodiments of any of the methods described herein, the soluble VEGF receptor reduces the ability of VEGF to bind to one or more of VEGFR-1, VEGFR-2, and VEGFR-3. In some embodiments of any of the methods described herein, the AAV vector further comprises a secretion sequence.

[0061] Unless otherwise specified, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and therefore encode the same amino acid sequence.

[0062] The term "isolated" means altered or removed from the natural state. For example, a nucleic acid or peptide naturally present in a living animal is not "isolated", but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is "isolated". An isolated nucleic acid or protein may exist in a substantially purified form, or may exist in a non-natural environment, such as, for example, a host cell.

[0063] The terms "transfected," "transformed," or "transduced" refer to the process of transferring or introducing exogenous nucleic acid into a cell. A "transfected," "transformed," or "transduced" mammalian cell is a cell that has been transfected, transformed, or transduced with exogenous nucleic acid.

[0064] The term "expression" refers to the transcription and / or translation of a specific nucleotide sequence encoding a protein.

[0065] The term "transient expression" refers to the expression of a non-integrated coding sequence for a short period of time (eg, hours or days). A coding sequence transiently expressed in a cell (eg, a mammalian cell) is lost after multiple rounds of cell division.

[0066] The term "subject" is intended to include any mammal. In some embodiments, the subject is a rodent (e.g., rat or mouse), rabbit, sheep, goat, pig, dog, cat, non-human primate, or human. In some embodiments, the subject suffers from non-syndromic deafness or has the risk of developing non-syndromic deafness. In some embodiments, the subject has previously been identified as suffering from an inner ear disorder. In some embodiments, the subject has previously been diagnosed as suffering from an inner ear disorder. In some embodiments, the subject has been identified as suffering from drug-induced hearing loss. In some embodiments, the subject is an infant (e.g., a human infant).

[0067] Treatment is "therapeutically effective" when it results in a reduction in one or more of the number, severity, and frequency of one or more symptoms of a disease (eg, asymptomatic sensorineural hearing loss) in a subject (eg, a human).

[0068] The term "nucleic acid" or "polynucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) or a combination thereof in single-stranded or double-stranded form. Unless expressly limited, the term includes nucleic acids containing known analogs of natural nucleotides, which have binding properties similar to the reference nucleotides. Unless otherwise indicated, a specific nucleic acid sequence also implicitly includes complementary sequences as well as the sequences explicitly indicated. In some embodiments of any nucleic acid described herein, the nucleic acid is DNA. In some embodiments of any nucleic acid described herein, the nucleic acid is RNA.

[0069] The term "signal peptide" refers to a sequence present at the N-terminus of a nascent secretory protein but not present in a naturally occurring mature protein. After the signal peptide is translated, the "signal peptide" is cleaved by a protease (e.g., a signal peptidase). Signal peptides are known in the art. Non-limiting examples of signal peptides include: MEFFKKTALAALVMGFSGAALA (SEQ ID NO: 9) and MKYLLPTAAAGLLLLAAQPAMA (SEQ ID NO: 10).

[0070] The term "inner ear disorder" refers to a disorder caused by dysfunction of cells (e.g., hair cells, supporting cells, spiral ganglion neurons, macrophages, or Schwann cells) in or around the inner ear of a mammal. Non-limiting examples of inner ear disorders include, for example, sensorineural hearing loss (SNHL), noise-induced hearing loss, drug-induced hearing loss, age-related hearing loss, acoustic neuroma, neurofibromatosis type 2, auditory neuropathy, noise-induced cochlear synaptopathy without hair cell loss, age-related cochlear synaptopathy, acquired sensorineural hearing loss, and vestibular schwannoma. See, e.g., Kujawa et al., Hear Res 330 (0 0): 191-199, 2015; and Suzuki et al., Scientific Reports 6: 24907. Non-limiting examples of inner ear disorders are described herein, and other examples of inner ear disorders are known in the art.

[0071] The term "antibody" means a complex of two or more single polypeptide chains that interact to form at least one antigen binding domain. Non-limiting examples of antibodies include monoclonal antibodies (e.g., full-length or complete monoclonal antibodies), polyclonal antibodies, multivalent antibodies, multispecific antibodies (e.g., bispecific, trispecific, etc. antibodies, as long as they exhibit the desired biological activity). Antibodies can be human, humanized and / or affinity matured.

[0072] The term "antigen-binding antibody fragment" is a single polypeptide that includes all of the amino acids that constitute at least one antigen-binding domain (eg, scFv).

[0073] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical, except for possible naturally occurring mutations that may be present in trace amounts. Monoclonal antibodies are highly specific (directed at a single antigen). In addition, in contrast to polyclonal antibody preparations that typically include different antibodies directed at different determinants (epitopes), each monoclonal antibody is directed at a single determinant on the antigen.

[0074] The monoclonal antibodies herein specifically include "chimeric" antibodies, as well as fragments of such antibodies, in which a portion of the heavy chain and / or light chain is identical or homologous to the corresponding sequence in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical or homologous to the corresponding sequence in antibodies derived from other species or belonging to other antibody classes or subclasses, as long as it exhibits the desired biological activity (see, e.g., U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984)).

[0075] An "antigen binding domain" is one or more protein domains (e.g., formed by the amino acids of a single polypeptide or formed by the amino acids of two or more polypeptides (e.g., the same or different polypeptides)) that are capable of specifically binding to one or more different antigens. In some examples, the antigen binding domain can bind to an antigen or epitope with a specificity and affinity similar to that of a naturally occurring antibody. In some embodiments, the antigen binding domain can include an alternative scaffold. Non-limiting examples of antigen binding domains are described herein. Other examples of antigen binding domains are known in the art. In some examples, the antigen binding domain can bind to a single antigen.

[0076] "Affinity" refers to the strength of the sum of non-covalent interactions between an antigen binding site and its binding partner (e.g., an antigen or epitope). Unless otherwise indicated, as used herein, "affinity" refers to the intrinsic binding affinity that reflects a 1:1 interaction between a member of an antigen binding domain and an antigen or epitope. The affinity of a molecule X for its partner Y can be expressed in terms of the dissociation equilibrium constant (K D ). Affinity can be measured by common methods known in the art, including those described herein. Affinity can be measured, for example, using surface plasmon resonance (SPR) technology (e.g., ) or biolayer interferometry (e.g. Other methods for determining the affinity between an antigen binding domain and its corresponding antigen or epitope are known in the art.

[0077] The phrase "half-life" refers to the half-life of an antibody, antigen-binding antibody fragment thereof, or soluble VEGF receptor in the circulation (e.g., blood) of a mammal (e.g., any mammal described herein), and is represented by the time required for 50% of the antibody, antigen-binding antibody fragment thereof, or soluble VEGF receptor to be cleared from the circulation. In some embodiments, a change in half-life (e.g., a decrease in the half-life of an antibody, antigen-binding antibody fragment thereof, or soluble VEGF receptor) is determined by comparing the half-life of an antibody, antigen-binding antibody fragment, or soluble VEGF receptor in a subject with the half-life of a control antibody, control antigen-binding antibody fragment, or control soluble VEGF receptor in a similar mammal.

[0078] In some embodiments, the half-life of an antibody, an antigen-binding antibody fragment thereof, or a soluble VEGF receptor in a mammal is determined by measuring the level of the antibody, an antigen-binding antibody fragment thereof, or a soluble VEGF receptor in a sample (e.g., a blood sample) obtained from a subject at different time points after systemic administration (e.g., intravenous administration) of any AAV vector described herein. In some embodiments, an enzyme-linked immunosorbent assay (ELISA) or another assay known in the art is used to determine the level of the antibody, an antigen-binding antibody fragment thereof, or a soluble VEGF receptor present in a sample obtained from a mammal, and the determined level of the antibody, an antigen-binding antibody fragment thereof, or a soluble VEGF receptor present in the sample is plotted as a function of time using a software program (e.g., GraphPad Prism).

[0079] The term "VEGF activity" refers to one or more known activities of a VEGF protein. For example, one activity of a VEGF protein is the ability to bind to one or more VEGF receptors. In another example, one activity of a VEGF protein is the ability of VEGF to trigger a downstream signal transduction pathway in a mammalian cell expressing a VEGF receptor. Methods for detecting one or more activities of VEGF are known in the art.

[0080] The term "soluble VEGF receptor" refers to a polypeptide comprising a portion of the extracellular region of one or more mammalian VEGF receptors (e.g., VEGFR-1, VEGFR-2, and VEGFR-3) operably linked to a signal peptide, wherein the soluble VEGF receptor is capable of specifically binding to one or more mammalian VEGF proteins (e.g., one or more of VEGF-A, VEGF-B, VEGF-C, and VEGF-D). In some examples, the soluble VEGF receptor comprises a portion of the extracellular region of VEGFR-1 (e.g., a continuous sequence from wild-type human VEGFR-1 (e.g., one or more immunoglobulin-like domains in the extracellular region from wild-type human VEGFR-1) or a sequence having at least 90% identity to a continuous sequence from wild-type human VEGFR-1). In some examples, the soluble VEGF receptor includes a portion of the extracellular region of VEGFR-2 (e.g., a contiguous sequence from wild-type human VEGFR-2 (e.g., one or more immunoglobulin-like domains in the extracellular region of wild-type human VEGFR-2) or a sequence that is at least 90% identical to a contiguous sequence from wild-type human VEGFR-2). In some examples, the soluble VEGF receptor includes a portion of the extracellular region of VEGFR-1 and a portion of the extracellular region of VEGFR-2 (e.g., one or more immunoglobulin-like domains in the extracellular region of wild-type human VEGFR-1 and one or more immunoglobulin-like domains in the extracellular region of wild-type human VEGFR-2) (e.g., aflibercept). In some examples, the soluble VEGF receptor includes a portion of the extracellular region of VEGFR-3 (e.g., a contiguous sequence from wild-type human VEGFR-3 (e.g., one or more immunoglobulin-like domains in the extracellular region of wild-type human VEGFR-3) or a sequence that is at least 90% identical to a contiguous sequence from wild-type human VEGFR-3).

[0081] In some examples, the soluble VEGF receptor may also include a stabilizing domain (e.g., an Fc domain, such as an IgG1 Fc domain (e.g., a human wild-type IgG1 Fc domain). In some examples, the soluble VEGF receptor reduces the ability of VEGF to bind to one or more (e.g., two or three) of VEGFR-1, VEGFR-2, and VEGFR-3. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Methods and materials for use in the present invention are described herein; other suitable methods and materials known in the art may also be used. The materials, methods, and examples are illustrative only and are not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In the event of a conflict, the present specification, including definitions, will control. BRIEF DESCRIPTION OF THE DRAWINGS

[0082] Figure 1A is an exemplary AAV vector of 4474 bp, which includes a fragment encoding bevacizumab sequence.

[0083] Figure 1B is an exemplary AAV vector of 3814 bp, which includes a sequence encoding ranibizumab sequence.

[0084] Figure 1C is an exemplary AAV vector of 4573 bp, which includes sequences encoding ranibizumab and green fluorescent protein (GFP).

[0085] Figure 1D is an exemplary AAV vector of 3631 bp, which includes a vector encoding aflibercept sequence.

[0086] Figure 2 is a Western blot showing HEK cell expression of various anti-VEGF antibodies or antigen-binding antibody fragments or soluble VEGF receptors using exemplary AAV vectors described herein. Lane 1: Pre-stained PageRuler TM Protein ladder. Lane 2: untransfected / negative control. Lane 3: Figure 1A Lane 4: Transfection with AAV vectors shown in Figure 1C Lane 5: Transfection with AAV vectors shown in Figure 1B Lane 6: AAV vector transfection with Figure 1A The AAV vector transfection shown in Figure 2 was performed with a multiplicity of infection (MOI) of 7.5 x 10 4 Lane 7: Figure 1A The AAV vectors shown were transfected at an MOI of 2.2x10 5 Lane 8: Figure 1A The AAV vector transfection shown in Figure 2 was performed with an MOI of 5.5 x 10 5 Lane 9: Pre-stained PageRuler TM Protein ladder. Lane 10: untransfected / negative control. Lane 11: Figure 1A Lane 12: Transfection with AAV vectors shown in Figure 1C Lane 13: Transfection with AAV vectors shown in Figure 1B Lane 14: Transfection with AAV vectors shown in Figure 1A The AAV vector transfection shown in Figure 2 was performed with a multiplicity of infection (MOI) of 7.5 x 10 4 Lane 15: with Figure 1A The AAV vectors shown were transfected at an MOI of 2.2x10 5 Lane 16: Figure 1A The AAV vector transfection shown in Figure 2 was performed with an MOI of 5.5 x 10 5 Lanes 2-8 contain reduced protein. Lanes 10-16 contain non-reduced protein.

[0087] Figure 3A is shown by using Analysis software Data Analysis HT10.0 Graph of the affinity of a control mouse anti-human VEGF monoclonal antibody (anti-hVEGF MmAb) in buffer using recombinant human VEGF as a binding agent as measured by the HTX biosensor instrument.

[0088] Figure 3B is shown by using Analysis software Data Analysis HT10.0 Plot of the affinity of control anti-hVEGF MmAb in conditioned media (CM) samples using recombinant human VEGF as binding agent, as measured by the HTX biosensor instrument. *: Anti-hVEGF MmAb was prepared at 100 μg / mL in CM and then diluted in 1x kinetic buffer to a final concentration of 10 μg / mL.

[0089] Figure 4A is shown by using Analysis software Data Analysis HT10.0 A graph of the affinity of conditioned media using recombinant human VEGF as a binding agent as measured by the HTX biosensor instrument.

[0090] Figure 4B is shown by using Analysis software Data Analysis HT10.0 HTX biosensor instrument, using recombinant human VEGF as a binding agent Figure 1A A graph showing the affinity of the culture medium of HEK cells transfected with AAV vectors.

[0091] Figure 4C It is shown by Figure 3A , Figure 3B , Figure 4A and Figure 4B The equilibrium dissociation constant (K) determined from the data shown D ) table (table from top to bottom). DETAILED DESCRIPTION

[0092] Provided herein are methods comprising introducing a therapeutically effective amount of an adeno-associated virus (AAV) vector into the inner ear of a mammal, wherein the AAV vector comprises a nucleotide sequence encoding: (a) a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide; or (b) a polypeptide comprising an antigen-binding antibody fragment (e.g., Fab or scFv) operably linked to a signal peptide.

[0093] Also provided herein is a method for increasing the level of antibodies or antigen-binding antibody fragments in the inner ear of a mammal in need thereof, the method comprising: introducing a therapeutically effective amount of an AAV vector into the inner ear of the mammal, the AAV vector comprising a nucleotide sequence encoding the following polypeptides: (a) a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide; or (b) a polypeptide comprising an antigen-binding antibody fragment (e.g., Fab or scFv) operably linked to a signal peptide; wherein the introduction results in an increase in the level of antibodies or antigen-binding antibody fragments in the inner ear of the mammal.

[0094] Also provided is a method for treating an inner ear disorder in a mammal in need thereof, the method comprising: introducing a therapeutically effective amount of an AAV vector into the inner ear of the mammal, the AAV vector comprising a nucleotide sequence encoding the following polypeptides: (a) a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide; or (b) a polypeptide comprising an antigen-binding antibody fragment linked to a signal peptide; wherein the introduction results in the treatment of the inner ear disorder in the mammal.

[0095] Also provided herein is a method for reducing VEGF activity in the inner ear of a mammal in need thereof, the method comprising: introducing a therapeutically effective amount of an AAV vector into the inner ear of the mammal, the AAV vector comprising a nucleotide sequence encoding the following polypeptides: (a) a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide; or (b) a polypeptide comprising an antigen-binding antibody fragment (e.g., Fab or scFv) operably linked to a signal peptide; wherein the polypeptide of (a) encodes an antibody that specifically binds to VEGF and reduces VEGF activity, and the polypeptide of (b) encodes an antigen-binding antibody fragment that specifically binds to VEGF and reduces VEGF activity; and wherein the introduction results in a reduction in VEGF activity in the inner ear of the mammal.

[0096] The present invention also provides a method for treating an acoustic neuroma, a vestibular schwannoma, or neurofibromatosis type II in the inner ear of a mammal, the method comprising: introducing a therapeutically effective amount of an AAV vector into the inner ear of the mammal, the AAV vector comprising a nucleotide sequence encoding the following polypeptides: (a) a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide; or (b) a polypeptide comprising an antigen-binding antibody fragment (e.g., Fab or scFv) operably linked to a signal peptide; wherein the polypeptide of (a) encodes an antibody that specifically binds to VEGF and reduces VEGF activity, and the polypeptide of (b) encodes an antigen-binding antibody fragment that specifically binds to VEGF and reduces VEGF activity; and wherein the introduction results in the treatment of an acoustic neuroma or a vestibular schwannoma in the inner ear of the mammal.

[0097] Also provided herein is a method comprising introducing into the inner ear of a mammal a therapeutically effective amount of an adeno-associated viral (AAV) vector comprising a nucleotide sequence encoding a soluble vascular endothelial growth factor (VEGF) receptor operably linked to a signal peptide.

[0098] Also provided herein is a method for increasing the level of soluble vascular endothelial growth factor (VEGF) receptor in the inner ear of a mammal in need thereof, the method comprising: introducing a therapeutically effective amount of an AAV vector into the inner ear of the mammal, the AAV vector comprising a nucleotide sequence encoding a soluble VEGF receptor operably linked to a signal peptide; wherein the introduction results in an increase in the level of soluble VEGF receptor in the inner ear of the mammal.

[0099] Also provided herein is a method for treating an inner ear disorder in a mammal in need thereof, the method comprising: introducing a therapeutically effective amount of an AAV vector into the inner ear of the mammal, the AAV vector comprising a nucleotide sequence encoding a soluble vascular endothelial growth factor (VEGF) receptor operably linked to a signal peptide; wherein the introduction results in the inner ear disorder being treated in the mammal.

[0100] Also provided herein is a method for reducing VEGF activity in the inner ear of a mammal in need thereof, the method comprising: introducing a therapeutically effective amount of an AAV vector into the inner ear of the mammal, the AAV vector comprising a nucleotide sequence encoding a soluble vascular endothelial growth factor (VEGF) receptor operably linked to a signal peptide; wherein the introduction results in reduced VEGF activity in the inner ear of the mammal.

[0101] The present invention also provides a method for treating an acoustic neuroma, a vestibular schwannoma or neurofibromatosis type 2 in the inner ear of a mammal, the method comprising: introducing a therapeutically effective amount of an AAV vector into the inner ear of the mammal, the AAV vector comprising a nucleotide sequence encoding a soluble vascular endothelial growth factor (VEGF) receptor operably linked to a signal peptide; wherein the introduction results in the treatment of an acoustic neuroma, a vestibular schwannoma or neurofibromatosis type II in the inner ear of the mammal, respectively.

[0102] Also provided are kits comprising any of the AAV vectors described herein.

[0103] Other non-limiting aspects of the compositions, kits, and methods are described herein, and may be used in any combination without limitation.

[0104] Antibodies and antigen-binding antibody fragments

[0105] In some embodiments, the antibody can be a humanized antibody, a chimeric antibody, or a multivalent antibody. In some embodiments, the antibody or antigen-binding antibody fragment can be a scFv-Fc, V H H domain, V NARIn some embodiments, the antibody or antigen-binding antibody fragment can be a DVD-Ig and a dual affinity repositioning antibody (DART), a trifunctional antibody (triomab), a kih IgG common LC, a crossmab, an orthogonal Fab IgG, a two-in-one IgG, an IgG-ScFv, a scFv2-Fc, a bispecific nanobody, a tandem antibody, a DART-Fc, a scFv-HAS-scFv, a DNL-Fab3, a DAF (two-in-one or four-in-one), a DutaMab, a DT-IgG, a knob-in-holes common LC, a knob-in-holes component (knobs-in-holes), a assembly), charge pair antibody, Fab arm exchange antibody, SEEDbody, trifunctional antibody, LUZ-Y, Fcab, kλ body, orthogonal Fab, DVD-IgG, IgG(H)-scFv, scFv-(H)IgG, IgG(L)-scFv, scFv-(L)-IgG, IgG(L,H)-Fc, IgG(H)-V, V(H)-IgG, IgG(L)-V, V(L)-IgG, KIH IgG-scFab, 2scFv-IgG, IgG-2scFv, scFv4-Ig, Zybody, DVI-IgG, nanobody, nanobody HSA, diabody, TandAb, scDiabody, scDiabody-CH3, diabody CH3, Triple Body, miniantibody, minibody, TriBi miniantibody, scFv-CH3 KIH, Fab-scFv, scFv-CH-CL-scFv, F(ab')2-scFV2, scFv-KIH, Fab-scFv-Fc, tetravalent HCAb, scDiabody-Fc, diabody Fc, tandem scFv-Fc, intrabody, dock and lock bispecific antibody, ImmTAC, HSAbody, scDiabody-HAS, tandem scFv, IgG-IgG, Cov-X-Body and scFv1-PEG-scFv2.

[0106] Other examples of antibody or antigen-binding antibody fragments include Fv fragments, Fab fragments, F(ab')2 fragments and Fab' fragments. Other examples of antibody or antigen-binding antibody fragments include: antigen-binding fragments of IgG (e.g., antigen-binding fragments of IgG1, IgG2, IgG3 or IgG4) (e.g., antigen-binding fragments of human or humanized IgG (e.g., human or humanized IgG1, IgG2, IgG3 or IgG4)); antigen-binding fragments of IgA (e.g., antigen-binding fragments of IgA1 or IgA2) (e.g., antigen-binding fragments of human or humanized IgA (e.g., human or humanized IgA1 or IgA2)); antigen-binding fragments of IgD (e.g., antigen-binding fragments of human or humanized IgD); antigen-binding fragments of IgE (e.g., antigen-binding fragments of human or humanized IgE); or antigen-binding fragments of IgM (e.g., antigen-binding fragments of human or humanized IgM).

[0107] Any of the antibodies or antigen-binding antibody fragments described herein can specifically bind to VEGF.

[0108] V H The H domain is a single monomeric variable antibody domain found in camelids. NAR The V domain is a single monomeric variable antibody domain found in cartilaginous fish. H H domain and V NARNon-limiting aspects of domains are described in, e.g., Cromie et al., Curr. Top. Med. Chem. 15:2543-2557, 2016; De Genst et al., Dev. Comp. Immunol. 30:187-198, 2006; De Meyer et al., Trends Biotechnol. 32:263-270, 2014; Kijanka et al., Nanomedicine 10:161-174, 2015; Kovaleva et al., Expert. Opin. Biol. Ther. 14:1527-1539, 2014; Krah et al., Immunopharmacol. Immunotoxicol. 38:21-28, 2016; Mujic-Delic et al., Trends Pharmacol. Sci. 35:247-255, 2014; Muyldermans, J. Biotechnol. 74:277-302, 2001; Muyldermans et al., Trends Biochem. Sci. 26:230-235, 2001; Muyldermans, Ann. Rev. Biochem. 82:775-797, 2013; Rahbarizadeh et al., Immunol. Invest. 40:299-338, 2011; Van Audenhove et al., EBioMedicine 8:40-48, 2016; Van Bockstaele et al., Curr. Opin. Investig. Drugs 10:1212-1224, 2009; Vincke et al., Methods Mol. Biol. 911: 15-26, 2012; and Wesolowski et al., Med. Microbiol. Immunol. 198: 157-174, 2009.

[0109] An "Fv" fragment comprises a non-covalently linked dimer of one heavy-chain and one light-chain variable domain.

[0110] In addition to the heavy and light chain variable domains of the Fv fragment, the "Fab" fragment also includes the constant domain of the light chain and the first constant domain of the heavy chain (C H1 ).

[0111] The "F(ab')2" fragment comprises two Fab fragments connected by a disulfide bond near the hinge region.

[0112] "Dual variable domain immunoglobulin" or "DVD-Ig" refers to multivalent and multispecific binding proteins as described in, e.g., DiGiammarino et al., Methods Mol. Biol. 899: 145-156, 2012; Jakob et al., MABs 5: 358-363, 2013; and U.S. Pat. Nos. 7,612,181; 8,258,268; 8,586,714; 8,716,450; 8,722,855; 8,735,546 and 8,822,645, each of which is incorporated by reference in its entirety.

[0113] DARTs are described, for example, in Garber, Nature Reviews Drug Discovery 13:799-801, 2014.

[0114] Other aspects of antibodies and antigen-binding antibody fragments are known in the art.

[0115] In some embodiments, any of the antibodies or antigen-binding antibody fragments described herein have a dissociation constant (K D ) is less than 1x 10 -5 M (e.g., less than 0.5 x 10 -5 M, less than 1x10 -6 M, less than 0.5x 10 -6 M, less than 1x 10 -7 M, less than 0.5x 10 -7 M, less than 1x 10 -8 M, less than 0.5x 10 -8 M, less than 1x 10 -9 M, less than 0.5x 10 -9 M, less than 1x 10 -10 M, less than 0.5x 10 -10 M, less than 1x 10 -11 M, less than 0.5x 10 -11 M or less than 1x 10 -12 M), e.g., as measured using surface plasmon resonance (SPR) in phosphate-buffered saline for a VEGF protein (e.g., any VEGF protein described herein, e.g., one or more of mature human VEGF-A, mature human VEGF-B, mature human VEGF-C, and mature human VEGF-D).

[0116] In some embodiments, any of the antibodies or antigen-binding antibody fragments described herein have a K D About 1x10 -12 M to about 1x 10 -5M, about 0.5x 10 -5 M, about 1x 10 -6 M, about 0.5x 10 -6 M, about 1x 10 -7 M, about 0.5x 10 -7 M, about 1x 10 -8 M, about 0.5x10 -8 M, about 1x 10 -9 M, about 0.5x 10 -9 M, about 1x 10 -10 M, about 0.5x 10 -10 M, about 1x 10 -11 M or about 0.5x 10 -11 M (including end value): about 0.5x 10 -11 M to about 1x10 -5 M, about 0.5x 10 -5 M, about 1x 10 -6 M, about 0.5x10 -6 M, about 1x 10 -7 M, about 0.5x 10 -7 M, about 1x 10 -8 M, about 0.5x 10 -8 M, about 1x 10 -9 M, about 0.5x10 -9 M, about 1x10 -10 M, about 0.5x 10 -10 M or about 1x 10 -11 M (including end value); about 1x 10 -11 M to about 1x 10 -5 M, about 0.5x 10 -5 M, about 1x 10 -6 M, about 0.5x10 -6 M, about 1x 10 -7 M, about 0.5x 10 -7 M, about 1x 10 -8 M, about 0.5x 10 -8 M, about 1x 10 -9 M, about 0.5x 10 -9 M, about 1x 10 -10 M or about 0.5x 10 -10 M (including end value): about 0.5x 10 -10 M to about 1x 10 -5 M, about 0.5x 10 -5 M, about 1x 10 -6 M, about 0.5x 10 -6M, about 1x 10 -7 M, about 0.5x 10 -7 M, about 1x 10 -8 M, about 0.5x10 -8 M, about 1x 10 -9 M, about 0.5x 10 -9 M or about 1x 10 -10 M (including end value); about 1x 10 -10 M to about 1x 10 -5 M, about 0.5x 10 - 5 M, about 1x 10 -6 M, about 0.5x 10 -6 M, about 1x 10 -7 M, about 0.5x 10 -7 M, about 1x 10 -8 M, about 0.5x 10 -8 M, about 1x10 -9 M or about 0.5x 10 -9 M (including end value): about 0.5x 10 -9 M to about 1x 10 -5 M, about 0.5x 10 -5 M, about 1x 10 -6 M, about 0.5x 10 -6 M, about 1x 10 -7 M, about 0.5x10 -7 M, about 1x 10 -8 M, about 0.5x 10 -8 M or about 1x 10 -9 M (including end value); about 1x 10 -9 M to about 1x 10 -5 M, about 0.5x 10 -5 M, about 1x 10 -6 M, about 0.5x 10 -6 M, about 1x 10 -7 M, about 0.5x 10 - 7 M, about 1x 10 -8 M or about 0.5x 10 -8 M (including end value): about 0.5x 10 -8 M to about 1x 10 -5 M, about 0.5x 10 -5 M, about 1x10 -6 M, about 0.5x 10 -6 M, about 1x 10 -7 M, about 0.5x 10-7 M or about 1x 10 -8 M (including end value); about 1x 10 -8 M to about 1x10 -5 M, about 0.5x 10 -5 M, about 1x 10 -6 M, about 0.5x 10 -6 M, about 1x 10 -7 M or about 0.5x 10 -7 M (including end value): about 0.5x 10 -7 M to about 1x 10 -5 M, about 0.5x 10 -5 M, about 1x 10 -6 M, about 0.5x 10 -6 M or about 1x 10 -7 M (including end value); about 1x 10 -7 M to about 1x 10 -5 M, about 0.5x 10 -5 M, about 1x 10 -6 M or about 0.5x 10 -6 M (including end value): about 0.5x 10 -6 M to about 1x 10 -5 M, about 0.5x 10 -5 M or about 1x 10 -6 M (including end value); about 1x 10 -6 M to about 1x10 -5 M or about 0.5x 10 -5 M (inclusive); or about 0.5 x 10 -5 M to about 1x 10 -5 M (inclusive), e.g., as measured using surface plasmon resonance (SPR) in phosphate-buffered saline for a VEGF protein (e.g., any VEGF protein described herein, e.g., one or more of mature human VEGF-A, mature human VEGF-B, mature human VEGF-C, and mature human VEGF-D).

[0117] The K of any of the antibodies or antigen-binding antibody fragments described herein can be determined using a variety of different methods known in the art. D values ​​(e.g., electrophoretic mobility shift assays, filter binding assays, surface plasmon resonance, and biomolecule binding kinetics assays, etc.).

[0118] In some embodiments of any of the antibodies and / or antigen-binding antibody fragments described herein, the half-life of the antibody and / or antigen-binding antibody fragment in a subject (e.g., a human) is shortened by about 0.5-fold to about 4-fold (e.g., about 0.5-fold to about 3.5-fold, about 0.5-fold to about 3-fold, about 0.5-fold to about 2.5-fold, about 0.5-fold to about 2-fold, about 0.5-fold to about 1.5-fold, about 0.5-fold to about 2.5-fold, about 0.5-fold to about 2-fold, about 0.5-fold to about 1.5-fold, about 0.5-fold to about 2.5-fold) compared to the half-life of a control antibody and / or control antigen-binding antibody fragment (e.g., any control antibody and / or control antigen-binding antibody fragment described herein) in a similar subject. fold, about 1-fold to about 4-fold, about 1-fold to about 3.5-fold, about 1-fold to about 3-fold, about 1-fold to about 2.5-fold, about 1-fold to about 2-fold, about 1.5-fold to about 4-fold, about 1.5-fold to about 3.5-fold, about 1.5-fold to about 3-fold, about 1.5-fold to about 2.5-fold, about 1.5-fold to about 2-fold, about 2-fold to about 4-fold, about 2-fold to about 3.5-fold, about 2-fold to about 3-fold, about 2-fold to about 2.5-fold, about 2.5-fold to about 4-fold, about 2.5-fold to about 3.5-fold, about 2.5-fold to about 3-fold, about 2.5-fold to about 4-fold, about 2.5-fold to about 3.5-fold, about 2.5-fold to about 3-fold, about 3-fold to about 4-fold, about 3-fold to about 3.5-fold, or about 3.5-fold to about 4-fold). See, e.g., Leabman et al., MAbs. 5(6):896-903, 2013. In some embodiments, an antibody or antigen-binding antibody fragment described herein has one or more amino acid substitutions in the Fc region that shorten its half-life in a mammal, and the control antibody lacks at least one (e.g., lacks all) of these one or more amino acid substitutions in the Fc region.

[0119] VEGF

[0120] The VEGF gene encodes vascular endothelial growth factor (VEGF), formerly known as fms-like tyrosine kinase (Flt-1). VEGF protein is a heparin-inhibitory protein that induces migration and proliferation of vascular endothelial cells.

[0121] Non-limiting examples of protein and nucleotide sequences encoding wild-type VEGF proteins are shown below.

[0122] Human VEGF transcript variant 1 protein sequence (SEQ ID NO: 1)

[0123]

[0124] Human VEGF transcript variant 1 cDNA (SEQ ID NO: 2)

[0125]

[0126] Human VEGF transcript variant 3 protein sequence (SEQ ID NO: 3)

[0127]

[0128] Human VEGF transcript variant 3 cDNA (SEQ ID NO: 4)

[0129]

[0130] Mature human VEGF-A (SEQ ID NO:13)

[0131]

[0132] Mature human VEGF-B (SEQ ID NO: 14)

[0133]

[0134] Mature human VEGF-C (SEQ ID NO: 15)

[0135]

[0136] Mature human VEGF-D (SEQ ID NO: 16)

[0137]

[0138] In some examples of any of the antibodies and antigen-binding fragments thereof described herein, the antibodies and antigen-binding fragments can bind to a VEGF antigen (e.g., any of the exemplary VEGF proteins described herein, e.g., one or more of mature human VEGF-A, mature human VEGF-B, mature human VEGF-C, and mature human VEGF-D) (e.g., any binding affinity described herein).

[0139] In some embodiments described herein, the antibody or antigen-binding antibody fragment can reduce the activity of VEGF (e.g., one or more of any of the exemplary VEGF proteins described herein, e.g., one or more of mature human VEGF-A, mature human VEGF-B, mature human VEGF-C, and mature human VEGF-D). In some embodiments, the antibody or antigen-binding antibody fragment can block the binding of VEGF (e.g., one or more of any of the exemplary VEGF proteins described herein, e.g., one or more of mature human VEGF-A, mature human VEGF-B, mature human VEGF-C, and mature human VEGF-D) to one or more of its receptors (e.g., one or more VEGF receptors). See, e.g., WO 1998 / 045331, US 9,079,953, US 2015 / 0147317, US 2016 / 0289314, Plotkin et al., Otology & Neurotology 33: 1046-1052 (2012); and Ferrara et al., (2005) Biochem Biophys Res Commun 333(2): 328-335. In some embodiments, the antibody or antigen-binding antibody can reduce downstream signaling (e.g., downstream signaling of a VEGF receptor (e.g., one or more of any of the exemplary VEGF receptors described herein, e.g., one or more of human VEGFR-1, human VEGFR-2, and human VEGFR-3)). In some embodiments, a decrease in VEGF activity can be detected indirectly, for example, by an increase in hearing in a mammal (e.g., an increase in hearing of 1% to about 400% (or any subrange of this range described herein)) or a decrease in the size or severity of one or more symptoms of an acoustic neuroma, vestibular schwannoma, or neurofibromatosis type II (e.g., a decrease of 1% to 99%, 1% to 95%, 1% to 90%, 1% to 85%, 1% to 80%, 1% to 75%, 1% to 70%, 1% to 65%, 1% to 80%, ... %, 1% to 60%, 1% to 55%, 1% to 50%, 1% to 45%, 1% to 40%, 1% to 35%, 1% to 30%, 1% to 25%, 1% to 20%, 1% to 15%, 1% to 10%, 1% to 5%, 5% to 99%, 5% to 95%, 5% to 90%, 5% to 85%, 5% to 80%, 5% to 75%, 5% to 70%, 5% to 65%, 5% to 60%, 5% to 55%, 5% to 50%, 5% to 45%, 5% to 40%, 5% to 35%, 5% to 30%, 5% to 25%, 5% to 20%, 5% to 15%, 5% to 10%, 10% to 99%, 10% to 95%,10% to 90%, 10% to 85%, 10% to 80%, 10% to 75%, 10% to 70%, 10% to 65%, 10% to 60%, 10% to 55%, 10% to 50%, 10% to 45%, 10% to 40%, 10% to 35%, 10% to 30%, 10% to 25%, 10% to 20%, 10% to 1 5%, 15% to 99%, 15% to 95%, 15% to 90%, 15% to 85%, 15% to 80%, 15% to 75%, 15% to 70%, 15% to 65%, 15% to 60%, 15% to 55%, 15% to 50%, 15% to 45%, 15% to 40%, 15% to 35%, 15% to 30%, 15 % to 25%, 15% to 20%, 20% to 99%, 20% to 95%, 20% to 90%, 20% to 85%, 20% to 80%, 20% to 75%, 20% to 70%, 20% to 65%, 20% to 60%, 20% to 55%, 20% to 50%, 20% to 45%, 20% to 40%, 20% to 35% , 20% to 30%, 20% to 25%, 25% to 99%, 25% to 95%, 25% to 90%, 25% to 85%, 25% to 80%, 25% to 75%, 25% to 70%, 25% to 65%, 25% to 60%, 25% to 55%, 25% to 50%, 25% to 45%, 25% to 40%, 25% to 35%, 25% to 30%, 30% to 99%, 30% to 95%, 30% to 90%, 30% to 85%, 30% to 80%, 30% to 75%, 30% to 70%, 30% to 65%, 30% to 60%, 30% to 55%, 30% to 50%, 30% to 45%, 30% to 40%, 30% to 3 ...50%, 30% to 35%, 30% to 35%, 30% to 35%, 30% to 35%, 30% to 35%, 30% to 35%, 30% to 35 5% to 99%, 35% to 95%, 35% to 90%, 35% to 85%, 35% to 80%, 35% to 75%, 35% to 70%, 35% to 65%, 35% to 60%, 35% to 55%, 35% to 50%, 35% to 45%, 35% to 40%, 40% to 99%, 40% to 95%, 40% to 90% %, 40% to 85%, 40% to 80%, 40% to 75%, 40% to 70%, 40% to 65%, 40% to 60%, 40% to 55%, 40% to 50%, 40% to 45%, 45% to 99%, 45% to 95%, 45% to 90%, 45% to 85%, 45% to 80%, 45% to 75%, 45% to 70%, 45% to 65%, 45% to 60%, 45% to 55%, 45% to 50%, 50% to 99%, 50% to 95%, 50% to 90%, 50% to 85%, 50% to 80%, 50% to 75%, 50% to 70%, 50% to 65%, 50% to 60%, 50% to 55%, 55% to 99%,55% to 95%, 55% to 90%, 55% to 85%, 55% to 80%, 55% to 75%, 55% to 70%, 55% to 65%, 55% to 60%, 60% to 99%, 60% to 95%, 60% to 90%, 60% to 85%, 60% to 80%, 60% to 75%, 60% to 70%, 60% to 65%, 65% to 99%, 65% to 95%, 65% to 90%, 65% to 85%, 65% to 80%, 65% to 75%, %, 65% to 70%, 70% to 99%, 70% to 95%, 70% to 90%, 70% to 85%, 70% to 80%, 70% to 75%, 75% to 99%, 75% to 95%, 75% to 90%, 75% to 85%, 75% to 80%, 80% to 99%, 80% to 95%, 80% to 90%, 80% to 85%, 85% to 99%, 85% to 95%, 85% to 90%, 90% to 99%, 90% to 95%, or 95% to 99%). In some embodiments, the reduction in VEGF activity can be detected in an in vitro assay.

[0140] In some embodiments, the antibody that specifically binds to VEGF is bevacizumab or antigen-binding fragments thereof. Bevacizumab (full-length antibody approximately 150 kDa) inhibits all isoforms of VEGF-A. Bevacizumab was approved by the Food and Drug Administration (FDA) in 2004 for use in colon cancer at a dose of 4.0-7.5 mg / kg for intravenous (IV) administration over 2-3 weeks (plasma half-life of 21 days) and 1.25 mg / 0.05 mL for intravitreal (IVT) administration (half-life of 5.6 days). The K of bevacizumab for VEGF 165 (VEGF-A) is D is 58 pM. See, e.g., WO 2017 / 050825. In some embodiments, the antibody that specifically binds to VEGF is ranibizumab or an antigen-binding fragment thereof. Ranibizumab (approximately 50 kDa) inhibits all isoforms of VEGF-A. Bevacizumab was approved by the FDA in 2006 for ocular use at a dose of 4.0-7.5 mg / kg for intravenous (IV) administration over 2-3 weeks (plasma half-life of 0.5 days) and 0.5 mg / 0.05 mL for intravitreal (IVT) administration (half-life of 3.2 days). The K of ranibizumab for VEGF 165 (VEGF-A) is D is 46 pM. See, e.g., WO 2014 / 178078. In some embodiments, the antibody that specifically binds to VEGF is sevacizumab (APX003 / SIM-BD0801) or an antigen-binding fragment thereof.

[0141] Amino acids encoding the light chain of bevacizumab (SEQ ID NO: 5)

[0142]

[0143] Amino acids encoding the heavy chain of bevacizumab (SEQ ID NO: 6)

[0144]

[0145] In some embodiments of the antibodies and antigen-binding fragments thereof described herein that specifically bind to VEGF, the antibody or antigen-binding fragment thereof comprises a variable light chain domain that is or comprises a sequence that is at least 80% identical (e.g., at least 82%, at least 84%, at least 86%, at least 88%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98%, or at least 99% identical) to the variable light chain domain of bevacizumab; and / or comprises a variable heavy chain domain that is or comprises a sequence that is at least 80% identical (e.g., at least 82%, at least 84%, at least 86%, at least 88%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98%, or at least 99% identical) to the variable heavy chain domain of bevacizumab.

[0146] In some embodiments of antibodies and antigen-binding fragments thereof that specifically bind to VEGF as described herein, the antibody or its antigen-binding fragment comprises a variable light chain domain, which is or includes the variable light chain domain of bevacizumab; and / or a variable heavy chain domain, which is or includes the variable heavy chain domain of bevacizumab. In some embodiments of antibodies and antigen-binding fragments thereof that specifically bind to VEGF as described herein, the antibody or its antigen-binding fragment comprises a variable light chain domain, which is or includes the sequence of the variable light chain domain of bevacizumab, except that it includes one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen amino acid substitutions; and / or comprises a variable heavy chain domain, which is or includes the sequence of the variable heavy chain of bevacizumab, except that it includes one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen amino acid substitutions. In some embodiments, the first antigen binding domain includes three CDRs in the light chain variable domain of bevacizumab and / or three CDRs in the heavy chain variable domain of bevacizumab.

[0147] Amino acids encoding the light chain of ranibizumab (SEQ ID NO: 7)

[0148]

[0149] Amino acids encoding the heavy chain of ranibizumab (SEQ ID NO: 8)

[0150]

[0151] In some embodiments of the antibodies and antigen-binding fragments thereof described herein that specifically bind to VEGF, the antibody or antigen-binding fragment thereof comprises a variable light chain domain that is or comprises a sequence that is at least 80% identical (e.g., at least 82%, at least 84%, at least 86%, at least 88%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98%, or at least 99% identical) to the variable light chain domain of ranibizumab; and / or comprises a variable heavy chain domain that is or comprises a sequence that is at least 80% identical (e.g., at least 82%, at least 84%, at least 86%, at least 88%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98%, or at least 99% identical) to the variable heavy chain domain of ranibizumab.

[0152] In some embodiments of antibodies and antigen-binding fragments thereof that specifically bind to VEGF described herein, the antibody or its antigen-binding fragment comprises a variable light chain domain that is or includes the variable light chain domain of ranibizumab; and / or a variable heavy chain domain that is or includes the variable heavy chain domain of ranibizumab. In some embodiments of antibodies and antigen-binding fragments thereof that specifically bind to VEGF described herein, the antibody or its antigen-binding fragment comprises a variable light chain domain that is or includes the sequence of the variable light chain domain of ranibizumab, except that it includes one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen amino acid substitutions; and / or comprises a variable heavy chain domain that is or includes the sequence of the variable heavy chain of ranibizumab, except that it includes one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen amino acid substitutions. In some embodiments, the first antigen binding domain includes three CDRs in the light chain variable domain of ranibizumab and / or three CDRs in the heavy chain variable domain of ranibizumab.

[0153] Soluble VEGF receptor

[0154] A soluble VEGF receptor is a polypeptide comprising a portion of an extracellular region of one or more (e.g., two or three) mammalian VEGF receptors (e.g., one or more of VEGFR-1, VEGFR-2, and VEGFR-3) operably linked to a signal peptide (e.g., any of the exemplary signal peptides described herein), wherein the soluble VEGF receptor is capable of specifically binding to one or more mammalian VEGF proteins (e.g., one or more (e.g., two, three, or four) of VEGF-A, VEGF-B, VEGF-C, and VEGF-D, for example, one or more (e.g., two, three, or four) of human wild-type VEGF-A, human wild-type VEGF-B, human wild-type VEGF-C, and human wild-type VEGF-D).

[0155] In some examples, the soluble VEGF receptor includes a portion of the extracellular region of VEGFR-1 (e.g., about 10 amino acids to about 732 amino acids, about 10 amino acids to about 700 amino acids, about 10 amino acids to about 650 amino acids, about 10 amino acids to about 600 amino acids, about 10 amino acids to about 550 amino acids, about 10 amino acids to about 500 amino acids, about 10 amino acids to about 450 amino acids, about 10 amino acids to about 400 amino acids, about 10 amino acids to about 350 amino acids, about 10 amino acids to about 300 amino acids, about 10 amino acids to about 250 amino acids, about 10 amino acids to about 200 amino acids, about 10 amino acids to about 550 amino acids, about 10 amino acids to about 500 amino acids, about 10 amino acids to about 450 amino acids, about 10 amino acids to about 400 amino acids, about 10 amino acids to about 350 amino acids, about 10 amino acids to about 300 amino acids, about 10 amino acids to about 250 amino acids, about 10 amino acids to about 200 amino acids, about 10 amino acids to about about 150 amino acids, about 10 amino acids to about 100 amino acids, about 10 amino acids to about 50 amino acids, about 50 amino acids to about 732 amino acids, about 50 amino acids to about 700 amino acids, about 50 amino acids to about 650 amino acids, about 50 amino acids to about 600 amino acids, about 50 amino acids to about 550 amino acids, about 50 amino acids to about 500 amino acids, about 50 amino acids to about 450 amino acids, about 50 amino acids to about 400 amino acids, about 50 amino acids to about 350 amino acids, about 50 amino acids to about 300 amino acids, about 50 amino acids to about 250 amino acids, about 50 amino acids to about 200 amino acids, about 50 The present invention relates to a polypeptide comprising at least one amino acid sequence of the present invention and at least one amino acid sequence of the present invention. The polypeptide comprises at least one amino acid sequence of the present invention and at least one amino acid sequence of the present invention. 150 amino acids to about 150 amino acids, about 150 amino acids to about 732 amino acids, about 150 amino acids to about 700 amino acids, about 150 amino acids to about 650 amino acids, about 150 amino acids to about 600 amino acids, about 150 amino acids to about 550 amino acids, about 150 amino acids to about 500 amino acids, about 150 amino acids to about 450 amino acids, about 150 amino acids to about 400 amino acids, about 150 amino acids to about 350 amino acids, about 150 amino acids to about 300 amino acids, about 150 amino acids to about 250 amino acids, about 150 amino acids to about 200 amino acids, about 200 amino acids to about 732 amino acids,about 200 amino acids to about 700 amino acids, about 200 amino acids to about 650 amino acids, about 200 amino acids to about 600 amino acids, about 200 amino acids to about 550 amino acids, about 200 amino acids to about 500 amino acids, about 200 amino acids to about 450 amino acids, about 200 amino acids to about 400 amino acids, about 200 amino acids to about 350 amino acids, about 200 amino acids to about 300 amino acids, about 200 amino acids to about 250 amino acids, about 250 amino acids to about 732 amino acids, about 250 amino acids to about 700 amino acids, about 250 amino acids to about 650 amino acids, about 250 amino acids to about 600 amino acids, about 250 amino acids to about 550 amino acids, about 250 amino acids to about 500 amino acids, about 250 amino acids to about 450 amino acids, about 250 amino acids to about 400 amino acids, about 250 amino acids to about 350 amino acids, about 250 amino acids to about 300 amino acids, about 300 amino acids to about 732 amino acids, about 300 amino acids to about 700 amino acids, about 300 amino acids to about 650 amino acids, about 300 amino acids to about 600 amino acids, about 300 amino acids to about 550 amino acids, about 300 amino acids to about 500 amino acids, about 300 amino acids to about 450 amino acids, about 300 amino acids to about 400 amino acids, about 400 amino acids, about 300 amino acids to about 350 amino acids, about 350 amino acids to about 732 amino acids, about 350 amino acids to about 700 amino acids, about 350 amino acids to about 650 amino acids, about 350 amino acids to about 600 amino acids, about 350 amino acids to about 550 amino acids, about 350 amino acids to about 500 amino acids, about 350 amino acids to about 450 amino acids, about 350 amino acids to about 400 amino acids, about 400 amino acids to about 732 amino acids, about 400 amino acids to about 700 amino acids, about 400 amino acids to about 650 amino acids, about 400 amino acids to about 600 amino acids, about 400 amino acids to about 550 amino acids, about 400 amino acids to about 500 amino acids, about 400 amino acids to about 450 amino acids, about 450 amino acids to about 732 amino acids, about 450 amino acids to about 700 amino acids, about 450 amino acids to about 650 amino acids, about 450 amino acids to about 600 amino acids, about 450 amino acids to about 550 amino acids, about 450 amino acids to about 500 amino acids, about 500 amino acids to about 732 amino acids, about 500 amino acids to about 700 amino acids, about 500 amino acids to about 650 amino acids, about 500 amino acids to about 600 amino acids, about 500 amino acids to about 550 amino acids,about 550 amino acids to about 732 amino acids, about 550 amino acids to about 700 amino acids, about 550 amino acids to about 650 amino acids, about 550 amino acids to about 600 amino acids, about 600 amino acids to about 732 amino acids, about 600 amino acids to about 700 amino acids, about 600 amino acids to about 650 amino acids, about 650 amino acids to about 732 amino acids, about 650 amino acids to about 700 amino acids, or about 700 amino acids to about 732 amino acids (e.g., a contiguous sequence of wild-type human VEGFR-1 (e.g., including wild-type human VEGFR-1 (e.g., SEQ ID NO:23), or a sequence that is at least 80% (e.g., at least 82%, at least 84%, at least 86%, at least 88%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98%, or at least 99%) identical to a continuous sequence of wild-type human VEGFR-1, for example, a sequence that is at least 80% (e.g., at least 82%, at least 84%, at least 86%, at least 88%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98%, or at least 99%) identical to a continuous sequence in SEQ ID NO:23.

[0156] In some examples, the soluble VEGF receptor includes a portion of the extracellular region of VEGFR-2 (e.g., about 20 amino acids to about 745 amino acids, or any subrange of this range described herein) (e.g., a contiguous sequence of wild-type human VEGFR-2 (e.g., a contiguous sequence of one or more (e.g., one, two, three, four, five, six, or seven) immunoglobulin-like domains in the extracellular region of wild-type human VEGFR-2 (e.g., SEQ ID NO: 26)), or a sequence that is at least 80% (e.g., at least 82%, at least 84%, at least 86%, at least 88%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98%, or at least 99%) identical to a contiguous sequence of wild-type human VEGFR-2, e.g., a sequence that is identical to SEQ ID NO: 26). A sequence that has at least 80% (e.g., at least 82%, at least 84%, at least 86%, at least 88%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98% or at least 99%) identity to the contiguous sequence in ID NO:26).

[0157] In some examples, the soluble VEGF receptor includes a portion of the extracellular region of VEGFR-1 (e.g., any portion of the extracellular region of VEGFR-1 described herein) and a portion of the extracellular region of VEGFR-2 (e.g., (any portion of the extracellular region of VEGFR-2 described herein). For example, the soluble VEGF receptor may include one or more (e.g., two, three, four, five, six, or seven) immunoglobulin-like domains in the extracellular region of wild-type human VEGFR-1 and one or more (e.g., two, three, four, five, six, or seven) immunoglobulin-like domains in the extracellular region of wild-type human VEGFR-2 (e.g., aflibercept).

[0158] In some examples, the soluble VEGF receptor includes a portion of the extracellular region of VEGFR-3 (e.g., about 20 amino acids to about 751 amino acids, or any subrange of this range described herein) (e.g., a contiguous sequence of wild-type human VEGFR-3 (e.g., a contiguous sequence of one or more (e.g., one, two, three, four, five, six, or seven) immunoglobulin-like domains in the extracellular region of wild-type human VEGFR-3 (e.g., SEQ ID NO: 29)), or a sequence that is at least 80% (e.g., at least 82%, at least 84%, at least 86%, at least 88%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98%, or at least 99%) identical to a contiguous sequence of wild-type human VEGFR-3, e.g., a sequence that is identical to SEQ ID NO: 29). A sequence having at least 80% (e.g., at least 82%, at least 84%, at least 86%, at least 88%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98% or at least 99%) identity to the contiguous sequence in ID NO: 29).

[0159] The non-limiting examples of the extracellular regions of different mammalian VEGFR-1, different mammalian VEGFR-2 and different mammalian VEGFR-3 are described herein. The non-limiting examples of proteins and nucleotide sequences encoding wild-type VEGF receptor proteins are shown below. As will be appreciated by those skilled in the art, amino acid substitutions that are conservative between species are more likely to result in changes in protein function, while substitutions at amino acid positions that are not conservative between species are less likely to have an impact on protein function.

[0160] Human VEGF receptor 1 isoform 2 protein sequence (SEQ ID NO: 17)

[0161]

[0162] Human VEGF receptor 1 isoform 2 cDNA (SEQ ID NO: 18)

[0163]

[0164] Human VEGF receptor 1 isoform 3 protein sequence (SEQ ID NO: 19) (sFlt1-14)

[0165]

[0166] Human VEGF receptor 1 isoform 3 cDNA (SEQ ID NO: 20)

[0167]

[0168]

[0169] Human VEGF receptor 1 isoform 4 protein sequence (SEQ ID NO: 21)

[0170]

[0171] Human VEGF receptor 1 isoform 4 cDNA (SEQ ID NO: 22)

[0172]

[0173] Extracellular region of wild-type human VEGFR-1 (SEQ ID NO: 23) (the seven Ig-like domains are shown in bold and underlined)

[0174]

[0175] The extracellular region of wild-type mouse VEGFR-1 (SEQ ID NO: 24)

[0176]

[0177] Extracellular region of wild-type rat VEGFR-1 (SEQ ID NO: 25)

[0178]

[0179] Extracellular region of wild-type human VEGFR-2 (SEQ ID NO: 26) (the seven Ig-like domains are shown in bold and underlined)

[0180]

[0181] Extracellular region of wild-type mouse VEGFR-2 (SEQ ID NO: 27)

[0182]

[0183] Extracellular region of wild-type rat VEGFR-2 (SEQ ID NO: 28)

[0184]

[0185] Extracellular region of wild-type human VEGFR-3 (SEQ ID NO: 29) (seven Ig-like domains are shown in bold)

[0186]

[0187] Extracellular region of wild-type mouse VEGFR-3 (SEQ ID NO: 30)

[0188]

[0189] Extracellular region of wild-type rat VEGFR-3 (SEQ ID NO: 31)

[0190]

[0191] In some examples, the soluble VEGF receptor may further include a stabilizing domain (e.g., an Fc domain or a portion of an Fc domain). For example, the stabilizing domain may be an IgG1 Fc domain (e.g., a human wild-type IgG1 Fc domain or a portion thereof). For example, the stabilizing domain may be an IgG2 Fc domain (e.g., a human wild-type IgG2 Fc domain or a portion thereof). For example, the stabilizing domain may be an IgG3 Fc domain (e.g., a human wild-type IgG3 domain or a portion thereof).

[0192] Non-limiting examples of a human wild-type IgG1 Fc domain, a human wild-type IgG2 Fc domain, and a human wild-type IgG3 Fc domain are shown below.

[0193] Human wild-type IgG1 Fc domain (SEQ ID NO: 32)

[0194]

[0195] Human wild-type IgG2 Fc region (SEQ ID NO: 33)

[0196]

[0197] Human wild-type IgG3 Fc region (SEQ ID NO: 34)

[0198]

[0199] In some embodiments, the soluble VEGF receptor is aflibercept. Aflibercept comprises a portion of the extracellular domain of human VEGF receptors 1 and 2 (approximately 115 kDa in size) fused to the Fc portion of human IgG1. Aflibercept inhibits the activity of VEGF-A, VEGF-B, and PIGF. D is 0.49 pM. See, for example, WO 2017 / 218974.

[0200] Encoding the amino group of Aflibercept (SEQ ID NO: 12)

[0201]

[0202] In some embodiments of the soluble VEGF receptor, the soluble VEGF receptor comprises a sequence that is at least 80% identical (e.g., at least 82%, at least 84%, at least 86%, at least 88%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98%, or at least 99% identical) to SEQ ID NO:12.

[0203] In some embodiments of the soluble VEGF receptor, the soluble VEGF receptor includes an extracellular domain, which is or includes the sequence of SEQ ID NO: 12, except that it includes one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen amino acid substitutions in the sequence of SEQ ID NO: 12.

[0204] Other examples of soluble VEGF receptors are described in, e.g., Kendall et al., PNAS 90: 10705-10709, 1993; Kendall et al., Biochem Biophys Res Commun 226: 324-328, 1996; Failla et al., Int J Mol Sci 19(5): pii.E1306, 2018; and Jung et al., PLoS One 7(9): e44572.

[0205] Carrier

[0206] Recombinant AAV vectors or "rAAV" are typically composed of at least a transgene or a portion thereof and regulatory sequences, and optionally 5' and 3' AAV inverted terminal repeats (ITRs). Such recombinant AAV vectors are packaged into capsids and delivered to selected target cells (e.g., cochlear hair cells).

[0207] The AAV sequence of the vector generally includes cis-acting 5' and 3' ITR sequences (see, e.g., BJ Carter, "Handbook of Parvoviruses", P. Tijsser, ed., CRC Press, pp. 155-168, 1990). The length of a typical AAV ITR sequence is about 145 nucleotides. In some embodiments, at least 75% (e.g., at least 80%, at least 85%, at least 90%, or at least 95%) of a typical ITR sequence is incorporated into an AAV vector. The ability to modify these ITR sequences is within the technical scope of the art. (See, e.g., texts such as Sambrook et al., "Molecular Cloning. A Laboratory Manual", 2nd edition, Cold Spring Harbor Laboratory, New York, 1989; and K. Fisher et al., J Virol. 70:520532, 1996). In some embodiments, any coding sequence described herein is flanked by 5' and 3' AAV ITR sequences in an AAV vector. AAV ITR sequences can be obtained from any known AAV, including the currently identified AAV types.

[0208] An AAV vector as described herein may include any of the regulatory elements described herein (eg, one or more of a promoter, a polyadenylation (poly(A)) signal sequence, and an IRES).

[0209] In some embodiments, the vector is an adenovirus (see, e.g., Dmitriev et al., (1998) J. Virol. 72:9706-9713; and Poulin et al., J. Virol 8:10074-10086, 2010). In some embodiments, the vector is a retrovirus (see, e.g., Maier et al., (2010) Future Microbiol 5:1507-23).

[0210] The vectors provided herein can have different sizes. The choice of vector for use in any of the compositions, kits, and methods described herein can depend on the size of the vector.

[0211] In some embodiments, the vector may have a total number of nucleotides of up to 10 kb. In some embodiments, the viral vector may have a total number of nucleotides in the range of about 1 kb to about 2 kb, about 1 kb to about 3 kb, about 1 kb to about 4 kb, about 1 kb to about 5 kb, about 1 kb to about 6 kb, about 1 kb to about 7 kb, about 1 kb to about 8 kb, about 1 kb to about 9 kb, about 1 kb to about 10 kb, about 2 kb to about 3 kb, about 2 kb to about 4 kb, about 2 kb to about 5 kb, about 2 kb to about 6 kb, about 2 kb to about 7 kb, about 2 kb to about 8 kb, about 2 kb to about 9 kb, about 2 kb to about 10 kb, about 3 kb to about 4 kb, about 3 kb to about 5 kb, about 3 kb to about 6 kb, about 3 kb to about 7 kb, about 3 kb to about 8 kb, about 2 kb to about 9 kb, From about 4kb to about 8kb, from about 3kb to about 9kb, from about 3kb to about 10kb, from about 4kb to about 5kb, from about 4kb to about 6kb, from about 4kb to about 7kb, from about 4kb to about 8kb, from about 4kb to about 9kb, from about 4kb to about 10kb, from about 5kb to about 6kb, from about 5kb to about 7kb, from about 5kb to about 8kb, from about 5kb to about 9kb, from about 5kb to about 10kb, from about 6kb to about 7kb, from about 6kb to about 8kb, from about 6kb to about 9kb, from about 6kb to about 10kb, from about 7kb to about 8kb, from about 7kb to about 9kb, from about 7kb to about 10kb, from about 8kb to about 9kb, from about 8kb to about 10kb, or from about 9kb to about 10kb.

[0212] In some embodiments, the vector is a lentivirus and may have a total number of nucleotides of up to 8 kb. In some examples, the lentivirus may have a total number of nucleotides of about 1 kb to about 2 kb, about 1 kb to about 3 kb, about 1 kb to about 4 kb, about 1 kb to about 5 kb, about 1 kb to about 6 kb, about 1 kb to about 7 kb, about 1 kb to about 8 kb, about 2 kb to about 3 kb, about 2 kb to about 4 kb, about 2 kb to about 5 kb, about 2 kb to about 6 kb, about 2 kb to about 7 kb, about 2 kb to about 8 kb, From about 3 kb to about 4 kb, from about 3 kb to about 5 kb, from about 3 kb to about 6 kb, from about 3 kb to about 7 kb, from about 3 kb to about 8 kb, from about 4 kb to about 5 kb, from about 4 kb to about 6 kb, from about 4 kb to about 7 kb, from about 4 kb to about 8 kb, from about 5 kb to about 6 kb, from about 5 kb to about 7 kb, from about 5 kb to about 8 kb, from about 6 kb to about 8 kb, from about 6 kb to about 7 kb, or from about 7 kb to about 8 kb.

[0213] In some embodiments, the vector is an adenovirus and can have a total number of nucleotides of up to 8 kb. In some embodiments, the adenovirus can have a total number of nucleotides in the following ranges: about 1 kb to about 2 kb, about 1 kb to about 3 kb, about 1 kb to about 4 kb, about 1 kb to about 5 kb, about 1 kb to about 6 kb, about 1 kb to about 7 kb, about 1 kb to about 8 kb, about 2 kb to about 3 kb, about 2 kb to about 4 kb, about 2 kb to about 5 kb, about 2 kb to about 6 kb, about 2 kb to about 7 kb, about 2 kb to about 8kb, about 3kb to about 4kb, about 3kb to about 5kb, about 3kb to about 6kb, about 3kb to about 7kb, about 3kb to about 8kb, about 4kb to about 5kb, about 4kb to about 6kb, about 4kb to about 7kb, about 4kb to about 8kb, about 5kb to about 6kb, about 5kb to about 7kb, about 5kb to about 8kb, about 6kb to about 7kb, about 6kb to about 8kb, or about 7kb to about 8kb.

[0214] In some embodiments, the vector is an adeno-associated virus (AAV vector) and may include up to 5 kb of total nucleotides. In some embodiments, the AAV vector may include a total nucleotide count in the range of about 1 kb to about 2 kb, about 1 kb to about 3 kb, about 1 kb to about 4 kb, about 1 kb to about 5 kb, about 2 kb to about 3 kb, about 2 kb to about 4 kb, about 2 kb to about 5 kb, about 3 kb to about 4 kb, about 3 kb to about 5 kb, or about 4 kb to about 5 kb.

[0215] Any vector disclosed herein can be introduced into mammalian cells (e.g., inner ear cells, cochlear hair cells) using a variety of different methods known in the art. Non-limiting examples of methods for introducing nucleic acids into mammalian cells include: lipofection, transfection (e.g., calcium phosphate transfection, transfection using highly branched organic compounds, transfection using cationic polymers, dendrimer-based transfection, optical transfection, particle-based transfection (e.g., nanoparticle transfection) or transfection using liposomes (e.g., cationic liposomes)), microinjection, electroporation, cell squeezing, sonoporation, protoplast fusion, puncture transfection, hydrodynamic delivery, gene gun, magnetofection, viral transfection, and nuclear transfection.

[0216] Any vector described herein may also include a control sequence, e.g., a control sequence selected from the group consisting of a transcription initiation sequence, a transcription termination sequence, a promoter sequence, an enhancer sequence, an RNA splicing sequence, a polyadenylation (polyA) signal, and a Kozak consensus sequence. Non-limiting examples of these control sequences are described herein. In some embodiments, the promoter may be a natural promoter, a constitutive promoter, an inducible promoter, and / or a tissue-specific promoter.

[0217] Promoter

[0218] The term "promoter" means a DNA sequence recognized by an enzyme / protein in a mammalian cell that is required to initiate transcription of a specific gene. A promoter generally refers to, for example, a nucleotide sequence that binds to an RNA polymerase and / or any associated factors and initiates transcription therein. Non-limiting examples of promoters are described herein. Other examples of promoters are known in the art.

[0219] In some embodiments, a vector (e.g., an adeno-associated virus (AAV) vector) encoding an antibody (e.g., an antibody that specifically binds to VEGF or an antigen-binding antibody fragment thereof) may include a promoter and / or enhancer. The vector encoding the antibody or antigen-binding antibody fragment may include any promoter and / or enhancer described herein or known in the art.

[0220] In some embodiments, the promoter is an inducible promoter, a constitutive promoter, a mammalian cell promoter, a viral promoter, a chimeric promoter, an engineered promoter, a tissue-specific promoter, or any other type of promoter known in the art. In some embodiments, the promoter is an RNA polymerase II promoter, such as a mammalian RNA polymerase II promoter. In some embodiments, the promoter is an RNA polymerase III promoter, including but not limited to an H1 promoter, a human U6 promoter, a mouse U6 promoter, or a pig U6 promoter. The promoter will generally be a promoter that is capable of promoting transcription in inner hair cells. In some instances, the promoter is a cochlear-specific promoter or a cochlear-directed promoter.

[0221] Various promoters that can be used herein are known in the art. Non-limiting examples of promoters that can be used herein include: human EF1a, human cytomegalovirus (CMV) (U.S. Pat. No. 5,168,062), human ubiquitin C (UBC), mouse phosphoglycerate kinase 1, polyoma adenovirus, simian virus 40 (SV40), β-globin, β-actin, α-fetoprotein, γ-globin, β-interferon, γ-glutamyl transferase, mouse mammary tumor virus (MMTV), Rous sarcoma virus, rat insulin, glyceraldehyde-3-phosphate dehydrogenase, metallothionein II (MT II), amylase, cathepsin, MI muscarinic receptor, retroviral LTR (e.g., human T-cell leukemia virus HTLV), AAV ITR, interleukin-2, collagenase, platelet-derived growth factor, adenovirus 5E2, stromelysin, mouse MX gene, glucose-regulated protein (GRP78 and GRP94), alpha-2-macroglobulin, vimentin, class I MHC gene H-2κb, HSP70, proliferative protein, tumor necrosis factor, thyroid stimulating hormone alpha gene, immunoglobulin light chain, T cell receptor, HLA DQα and DQβ, interleukin-2 receptor, class II MHC, class II MHC HLA-DRα, muscle creatine kinase, prealbumin (transthyretin), elastase I, albumin gene, c-fos, c-HA-ras, neural cell adhesion molecule (NCAM), H2B (TH2B) histone, rat growth hormone, human serum amyloid protein (SAA), troponin I (TN I), Duchenne muscular dystrophy, human immunodeficiency virus and gibbon ape leukemia virus (GALV) promoter. Other examples of promoters are known in the art. See, e.g., Lodish, Molecular Cell Biology, Freeman and Company, New York 2007. In some embodiments, the promoter is a CMV immediate early promoter. In some embodiments, the promoter is a CAG promoter or a CAG / CBA promoter.

[0222] The term "constitutive" promoter refers to a nucleotide sequence that, when operably linked to a nucleic acid encoding a protein (eg, an antibody or antigen-binding antibody fragment), causes RNA to be transcribed from the nucleic acid in mammalian cells under most or all physiological conditions.

[0223] Examples of constitutive promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter, the cytomegalovirus (CMV) promoter (see, e.g., Boshart et al., Cell 41:521-530, 1985), the SV40 promoter, the dihydrofolate reductase promoter, the β-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1-α promoter (Invitrogen).

[0224] Inducible promoters allow for regulation of gene expression and can be regulated by the presence of exogenous compounds, environmental factors (such as temperature), or a specific physiological state (e.g., the acute phase, a specific differentiation state of the cell, or only in replicating cells). Inducible promoters and inducible systems are commercially available from a variety of commercial sources, including but not limited to Invitrogen, Clontech, and Ariad. Other examples of inducible promoters are known in the art.

[0225] Examples of inducible promoters regulated by exogenous compounds include the zinc-inducible sheep metallothionein (MT) promoter, the dexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV) promoter, the T7 polymerase promoter system (WO98 / 10088), the ecdysone insect promoter (No et al., Proc. Natl. Acad. Sci. USA 93:3346-3351, 1996), the tetracycline repressible system (Gossen ... ad. Sci. USA 89:5547-5551, 1992), tetracycline inducible system (Gossen et al., Science 268:1766-1769, 1995, see also Harvey et al., Curr. Opin. Chem. Biol. 2:512-518, 1998), RU486 inducible system (Wang et al., Nat. Biotech. 15:239-243, 1997) and Wang et al., Gene Ther. 4:432-441, 1997) and rapamycin inducible system (Magari et al., J. Clin. Invest. 100:2865-2872, 1997).

[0226] The term "tissue-specific" promoter refers to a promoter that is active only in certain specific cell types and / or tissues (eg, transcription of a particular gene occurs only in cells that express a transcriptional regulatory protein that binds to the tissue-specific promoter).

[0227] In some embodiments, the regulatory sequence confers tissue-specific gene expression capability. In some cases, the tissue-specific regulatory sequence binds a tissue-specific transcription factor that induces transcription in a tissue-specific manner.

[0228] Exemplary tissue-specific promoters include, but are not limited to, the following: liver-specific thyroxine binding globulin (TBG) promoter, insulin promoter, glucagon promoter, somatostatin promoter, pancreatic polypeptide (PPY) promoter, synapsin-1 (Syn) promoter, creatine kinase (MCK) promoter, mammalian desmin (DES) promoter, α-myosin heavy chain (a-MHC) promoter, and cardiac troponin T (cTnT) promoter. Other exemplary promoters include β-actin promoter, hepatitis B virus core promoter (Sandig et al., Gene Ther. 3: 1002-1009, 1996), alpha-fetoprotein (AFP) promoter (Arbuthnot et al., Hum. Gene Ther. 7: 1503-1514, 1996), osteocalcin promoter (Stein et al., Mol. Biol. Rep. 24: 185-196, 1997), bone sialoprotein promoter (Chen et al., J. Bone Miner. Res. 11: 654-664, 1996), CD2 promoter (Hansal et al., J. Immunol. 161: 1063-1068, 1998), immunoglobulin heavy chain promoter, T Cell receptor α chain promoter, neurons such as the neuron-specific enolase (NSE) promoter (Andersen et al., Cell. Mol. Neurobiol. 13:503-515, 1993), the neurofilament light chain gene promoter (Piccioli et al., Proc. Natl. Acad. Sci. USA 88:5611-5615, 1991), and the neuron-specific vgf gene promoter (Piccioli et al., Neuron 15:373-384, 1995).

[0229] In some embodiments, the tissue-specific promoter is a cochlear-specific promoter. In some embodiments, the tissue-specific promoter is a cochlear hair cell-specific promoter. Non-limiting examples of cochlear hair cell-specific promoters include, but are not limited to, ATOH1 promoter, POU4F3 promoter, LHX3 promoter, MYO7A promoter, MYO6 promoter, α9ACHR promoter, and α10ACHR promoter. In some embodiments, the promoter is a cochlear hair cell-specific promoter, such as a PRESTIN promoter or an ONCOMOD promoter. See, for example, Zheng et al., Nature 405: 149-155, 2000; Tian et al., Dev. Dyn. 231: 199-203, 2004; and Ryan et al., Adv. Otorhinolaryngol. 66: 99-115, 2009.

[0230] Enhancer

[0231] In some cases, a vector (e.g., an AAV vector) may include an enhancer sequence. The term "enhancer" refers to a nucleotide sequence that can increase the transcription level of a nucleic acid encoding a protein of interest (e.g., an antibody or antigen-binding antibody fragment thereof that specifically binds to VEGF or a soluble VEGF receptor). Enhancer sequences (50-1500 base pairs in length) typically increase transcription levels by providing additional binding sites for transcription-related proteins (e.g., transcription factors). In some embodiments, enhancer sequences are found within intron sequences. Unlike promoter sequences, enhancer sequences can work at a greater distance from the transcription start site (e.g., compared to a promoter). Non-limiting examples of enhancers include RSV enhancers, CMV enhancers, and SV40 enhancers.

[0232] Poly(A) signal sequence

[0233] In some embodiments, any vector provided herein (e.g., AAV vector) may include a polyadenylation (poly (A)) signal sequence. Most nascent eukaryotic mRNAs have a poly (A) tail added at their 3' end in a complex process, including cleavage of the initial transcript and a coupled polyadenylation reaction driven by a poly (A) signal sequence (see, e.g., Proudfoot et al., Cell 108: 501-512, 2002). The poly (A) tail confers mRNA stability and transferability (Molecular Biology of the Cell, 3rd edition B. Alberts et al., Garland Publishing, 1994). In some embodiments, the poly (A) signal sequence is located at the 3' end of the nucleic acid sequence encoding an antibody heavy chain, an antibody light chain, an antigen-binding antibody fragment, or a soluble VEGF receptor.

[0234] As used herein, "polyadenylation" refers to the covalent attachment of a polyadenylic acid moiety or a modified variant thereof to a messenger RNA molecule. In eukaryotes, most messenger RNA (mRNA) molecules are polyadenylated at the 3' end. The 3' poly (A) tail is a long sequence of adenine nucleotides (e.g., 50, 60, 70, 100, 200, 500, 1000, 2000, 3000, 4000, or 5000) added to the pre-mRNA by the action of an enzyme, polyadenylic acid polymerase. In higher eukaryotes, the poly (A) tail is added to transcripts containing a specific sequence (the polyadenylation (or poly (A)) signal). The poly (A) tail and the proteins to which it is bound help protect the mRNA from degradation by exonucleases. Polyadenylation is also important for transcription termination, mRNA export from the nucleus, and translation. After DNA is transcribed into RNA, polyadenylation occurs immediately in the nucleus, but can also occur later in the cytoplasm. After transcription is terminated, the mRNA chain is cleaved by the action of an endonuclease complex associated with RNA polymerase. The cleavage site is usually characterized by the presence of the base sequence AAUAAA near the cleavage site. After the mRNA has been cleaved, adenosine residues are added to the free 3' end at the cleavage site.

[0235] As used herein, a "poly(A) signal sequence" or "polyadenylation signal sequence" is a sequence that triggers endonuclease cleavage of an mRNA and adds a series of adenosines to the 3' end of the cleaved mRNA.

[0236] There are several poly(A) signal sequences that can be used, including those derived from bovine growth hormone (bgh) (Woychik et al., Proc. Natl. Acad. Sci. USA 81(13):3944-3948, 1984; U.S. Pat. No. 5,122,458), mouse β-globin, mouse α-globin (Orkin et al., EMBO J. 4(2):453-456, 1985; Thein et al., Blood 71(2):313-319, 1988), human collagen, polyomavirus (Batt et al., Mol. Cell Biol. 15(9):4783-4790, 1995), herpes simplex virus thymidine kinase gene (HSV TK), IgG heavy chain gene polyadenylation signal (US 2006 / 0040354), human growth hormone (hGH) (Szymanski et al., Mol. Therapy 15(7):1340-1347, 2007), a group consisting of the SV40 poly(A) site, such as the SV40 late and early poly(A) sites (Schek et al., Mol. Cell Biol. 12(12):5386-5393, 1992).

[0237] The poly (A) signal sequence can be AATAAA. The AATAAA sequence can be replaced by other hexanucleotide sequences that are homologous to AATAAA and capable of signaling polyadenylation, including ATTAAA, AGTAAA, CATAAA, TATAAA, GATAAA, ACTAAA, AATATA, AAGAAA, AATGAA, AATCAA, AACAAA, AATCAA, AATTAAC, AATTAGA, AATTAAA or AATAAG (see, e.g., WO 06 / 12414).

[0238] In some embodiments, the poly(A) signal sequence can be a synthetic polyadenylation site (see, e.g., Promega's pCl-neo expression vector, which is based on Levitt et al., Genes Dev. 3(7): 1019-1025, 1989). In some embodiments, the poly(A) signal sequence is the polyadenylation signal of soluble neuropilin-1 (sNRP) (AAATAAAATACGAAATG; SEQ ID NO: 11) (see, e.g., WO 05 / 073384). Other examples of poly(A) signal sequences are known in the art.

[0239] Internal ribosome entry site (IRES)

[0240] In some embodiments, a vector encoding an antibody (e.g., an antibody heavy chain and an antibody light chain), an antigen-binding antibody fragment, or a soluble VEGF receptor (e.g., an adeno-associated virus (AAV) vector) may include a polynucleotide internal ribosome entry site (IRES). An IRES sequence is used to produce more than one polypeptide from a single gene transcript. IRES forms a complex secondary structure that allows translation initiation to occur at any position of the mRNA immediately downstream of the location of the IRES (see, e.g., Pelletier and Sonenberg, Mol. Cell. Biol. 8(3): 1103-1112, 1988).

[0241] There are several IRES sequences known to those skilled in the art, including those from, for example, foot-and-mouth disease virus (FMDV), encephalomyocarditis virus (EMCV), human rhinovirus (HRV), cricket paralysis virus, human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis C virus (HCV), and poliovirus (PV). See, e.g., Alberts, Molecular Biology of the Cell, Garland Science, 2002; and Hellen et al., Genes Dev. 15(13):1593-612, 2001.

[0242] In some embodiments, the IRES sequence incorporated into the AAV vector is the foot-and-mouth disease virus (FMDV) 2A sequence. The foot-and-mouth disease virus 2A sequence is a small peptide (about 18 amino acids in length) that has been shown to mediate the cleavage of polyproteins (Ryan, MD et al., EMBO 4:928-933, 1994; Mattion et al., J. Virology 70:8124-8127, 1996; Furler et al., Gene Therapy 8:864-873, 2001; and Halpin et al., Plant Journal 4:453-459, 1999). The cleavage activity of the 2A sequence has been previously demonstrated in artificial systems including plasmids and gene therapy vectors (AAV and retroviruses) (Ryan et al., EMBO 4:928-933, 1994; Mattion et al., J. Virology 70:8124-8127, 1996; Furler et al., Gene Therapy 8:864-873, 2001; and Halpin et al., Plant Journal 4:453-459, 1999; deFelipe et al., Gene Therapy 6:198-208, 1999; de Felipe et al., Human Gene Therapy 11:1921-1931, 2000; and Klump et al., Gene Therapy 8:811-817, 2001).

[0243] Report sequence

[0244] Any AAV provided herein may optionally include a sequence encoding a reporter protein ("reporter sequence"). Non-limiting examples of reporter sequences include DNA sequences encoding: β-lactamase, β-galactosidase (LacZ), alkaline phosphatase, thymidine kinase, green fluorescent protein (GFP), red fluorescent protein, mCherry fluorescent protein, yellow fluorescent protein, chloramphenicol acetyltransferase (CAT) and luciferase. Other examples of reporter sequences are known in the art. When associated with a regulatory element driving its expression, the reporter sequence can provide a signal that can be detected by conventional means, including enzymatic, ray detection, colorimetric, fluorescence or other spectrometric determinations; Fluorescence activated cell sorting (FACS) determination; Immunoassays (e.g., enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and immunohistochemistry).

[0245] In some embodiments, the reporter sequence is a LacZ gene, and the presence of a vector carrying the LacZ gene in a mammalian cell (e.g., a cochlear hair cell) is detected by measuring β-galactosidase activity. When the reporter gene is a fluorescent protein (e.g., green fluorescent protein) or luciferase, the presence of a vector carrying a fluorescent protein or luciferase in a mammalian cell (e.g., a cochlear hair cell) can be measured by light generation in a fluorescence technique (e.g., fluorescent microscopy or FACS) or a photometer (e.g., a spectrophotometer or IVIS imaging instrument). In some embodiments, the reporter sequence can be used to verify the tissue-specific targeting ability and tissue-specific promoter regulation activity of any vector described herein.

[0246] Flanking untranslated region (UTR)

[0247] In some embodiments, any adeno-associated virus (AAV) vector may include an untranslated region, such as a 5'UTR or a 3'UTR.

[0248] The untranslated region (UTR) of a gene is transcribed but not translated. The 5'UTR starts at the transcription start site and continues to the start codon, but does not include the start codon. The 3'UTR starts immediately after the stop codon and continues until the transcription termination signal. There is increasing evidence that UTR plays a regulatory role in the stability and translation of nucleic acid molecules. The regulatory features of UTR can be incorporated into any vector, composition, kit or method as described herein to enhance the expression of an antibody (e.g., an antibody that specifically binds to VEGF), an antigen-binding antibody fragment (e.g., an antigen-binding fragment that specifically binds to VEGF) or a soluble VEGF receptor.

[0249] Natural 5'UTRs include sequences that play a role in translation initiation. They carry a signature similar to the Kozak sequence, which is generally known to be involved in the process by which the ribosome initiates translation of many genes. The Kozak sequence has a consensus sequence of CCR(A / G)CCAUGG, where R is a purine (A or G), three bases upstream of the start codon (AUG), and the start codon is followed by another "G". The 5'UTR is also known to form a secondary structure that is involved in the binding of elongation factors.

[0250] In some embodiments, a 5'UTR is included in any of the vectors described herein. Non-limiting examples of 5'UTRs include those from the following genes: albumin, serum amyloid A, apolipoprotein A / B / E, transferrin, alpha-fetoprotein, erythropoietin, and factor VIII, which can be used to enhance the expression of nucleic acid molecules such as mRNA.

[0251] In some embodiments, a 5'UTR from mRNA transcribed from cells in the cochlea can be included in any of the vectors, compositions, kits, and methods described herein.

[0252] It is known that many segments of adenosine and uridine (in RNA form) or thymidine (in DNA form) are embedded in 3'UTR. These AU-rich signatures are particularly common in genes with high turnover rates. Based on their sequence characteristics and functional properties, AU-rich elements (AREs) can be divided into three categories (Chen et al., Mol. Cell. Biol. 15: 5777-5788, 1995; Chen et al., Mol. Cell Biol. 15: 2010-2018, 1995): Class I ARE contains several copies of dispersed AUUUA motifs in U-rich regions. For example, c-Myc and MyoD mRNA contain Class I ARE. Class II ARE has two or more overlapping UUAUUUA (U / A) (U / A) nonamers. GM-CSF and TNF-α mRNA are examples containing Class II ARE. The definition of Class III ARE is not very clear. These U-rich regions do not contain AUUUA motifs. Two well-studied examples of these categories are c-Jun and myogenin mRNA.

[0253] Most proteins that bind to AREs are known to destabilize the message, while members of the ELAV family, most notably HuR, have been shown to increase mRNA stability. HuR binds to all three classes of AREs. Engineering a HuR-specific binding site into the 3'UTR of a nucleic acid molecule will result in HuR binding and, therefore, stabilization of the message in vivo.

[0254] In some embodiments, the introduction, removal or modification of the 3'UTR ARE can be used to regulate the stability of the mRNA encoding the protein of interest (e.g., any antibody described herein, any antigen-binding antibody fragment described herein, or any soluble VEGF receptor described herein). In other embodiments, the ARE can be removed or mutated to increase intracellular stability, and thus increase the translation and production of the protein of interest (e.g., any antibody described herein, any antigen-binding antibody fragment described herein, or any soluble VEGF receptor described herein).

[0255] In other embodiments, non-ARE sequences may be incorporated into the 5' or 3' UTR. In some embodiments, an intron or a portion of an intron sequence may be incorporated into the flanking region of a polynucleotide in any vector, composition, kit, and method provided herein. The incorporation of an intron sequence may increase protein production as well as mRNA levels.

[0256] Fc mutations that shorten the half-life of antibodies, antigen-binding antibody fragments, or soluble VEGF receptors in mammals

[0257] Any of the antibodies, antigen-binding antibody fragments, or soluble VEGF receptors described herein may include one or more (e.g., two, three, four, five, six, seven, eight, nine, or ten) amino acid substitutions in the Fc region, e.g., that shorten the half-life of the antibody, antigen-binding antibody fragment, or soluble VEGF receptor in a mammal compared to the half-life of an otherwise identical antibody, antigen-binding antibody fragment, or soluble VEGF receptor that does not include at least one of the one or more amino acid substitutions in the Fc region. Methods for determining the half-life of an antibody, antigen-binding antibody fragment, or soluble VEGF receptor in a mammal are well known in the art.

[0258] Non-limiting examples of point mutations in Fc mutations that can shorten the half-life of antibodies, antigen-binding antibody fragments, or soluble VEGF receptors are described in Leabman et al., MAbs 5(6):896-903, 2013.

[0259] method

[0260] Also provided herein are methods comprising introducing a therapeutically effective amount of an adeno-associated virus (AAV) vector into the inner ear of a mammal, wherein the AAV vector comprises a nucleotide sequence encoding: (a) a polypeptide comprising an antibody heavy chain variable domain (e.g., any exemplary antibody heavy chain variable domain described herein) operably linked to a signal peptide (e.g., any signal peptide described herein) and a polypeptide comprising an antibody light chain variable domain (e.g., any exemplary antibody light chain variable domain described herein) operably linked to a signal peptide (e.g., any signal peptide described herein); (b) a polypeptide comprising an antigen-binding antibody fragment (e.g., scFv) (e.g., any exemplary antigen-binding antibody fragment described herein) operably linked to a signal peptide (e.g., any signal peptide described herein), or (c) a soluble VEGF receptor (e.g., any soluble VEGF receptor described herein) operably linked to a signal peptide (e.g., any signal peptide described herein). Also provided herein are methods for increasing the level of an antibody or antigen-binding antibody fragment in the inner ear of a mammal in need thereof, the method comprising: introducing into the inner ear of the mammal a therapeutically effective amount of an AAV vector comprising a nucleotide sequence encoding: (a) a polypeptide comprising an antibody heavy chain variable domain (e.g., any antibody heavy chain variable domain described herein) operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain (e.g., any antibody light chain variable domain described herein) operably linked to a signal peptide; or (b) a polypeptide comprising an antigen-binding antibody fragment (e.g., scFv) (e.g., any exemplary antigen-binding antibody fragment described herein) operably linked to a signal peptide (e.g., any exemplary signal peptide described herein); wherein the introduction results in an increase in the level of the antibody or antigen-binding antibody fragment in the inner ear of the mammal, for example, compared to the level of the antibody or antigen-binding antibody fragment in the inner ear of the mammal before administration. or an increase in the level of antigen-binding antibody fragments (e.g., an increase of 1% to 400% (or any subrange of this range described herein), or an increase of at least 1%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, at least 200%, at least 250%, at least 300%, at least 350%, at least 400%, at least 450%, at least 50 ... %, at least 500%, at least 550%, at least 600%, at least 650%, at least 700%, at least 750%, at least 800%, at least 850%, at least 900%, at least 950%, at least 1000%, at least 1100%, at least 1200%, at least 1300%, at least 1400%, at least 1500%, at least 1600%, at least 1700%, at least 1800%, at least 1900% or at least 2000%).

[0261] Also provided herein are methods for increasing the level of a soluble VEGF receptor, the method comprising: introducing into the inner ear of a mammal a therapeutically effective amount of an AAV vector comprising a nucleotide sequence encoding a soluble VEGF receptor operably linked to a signal peptide (e.g., any signal peptide described herein); wherein the introduction results in, for example, an increase in the level of the soluble VEGF receptor in the inner ear of the mammal (e.g., an increase of 1% to 400% (or any subrange of this range described herein), or an increase of at least 1%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, at least 160%, at least 170%, at least 180%, at least 190%, at least 200%, at least 210%, at least 220%, at least 230%, at least 240%, at least 250%, at least 260%, at least 270%, at least 280%, at least 290%, at least 300%, at least 310%, at least 320%, at least 330%, at least 340%, at least 350%, at least 360%, at least 370%, at least 380%, at least 390%, at least 400%, at least 410%, at least 420%, at least 430%, at least 440%, at least 450%, at least 460%, at least 470%, at least 480%, at least 490%, at least 500%, at least 510%, at least 520%, at least 530%, at least 540%, at least 550%, at least 560%, at least 570%, at least 580%, at least %, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, at least 200%, at least 250%, at least 300%, at least 350%, at least 400%, at least 450%, at least 500%, at least 550%, at least 600%, at least 650%, at least 700%, at least 750%, at least 800%, at least 850%, at least 900%, at least 950%, at least 1000%, at least 1100%, at least 1200%, at least 1300%, at least 1400%, at least 1500%, at least 1600%, at least 1700%, at least 1800%, at least 1900 or at least 2000%).

[0262] Also provided herein are methods for treating an inner ear disorder in a mammal in need thereof, the method comprising: introducing into the inner ear of the mammal a therapeutically effective amount of an AAV vector comprising a nucleotide sequence encoding: (a) a polypeptide comprising an antibody heavy chain variable domain (e.g., any antibody heavy chain variable domain described herein) operably linked to a signal peptide (e.g., any signal peptide described herein) and a polypeptide comprising an antibody light chain variable domain (e.g., any antibody light chain variable domain described herein) operably linked to a signal peptide (e.g., any signal peptide described herein); (b) a polypeptide comprising an antigen-binding antibody fragment (e.g., any exemplary antigen-binding antibody fragment described herein) linked to a signal peptide (e.g., any signal peptide described herein); or (c) a soluble VEGF receptor (e.g., any soluble VEGR receptor described herein) operably linked to a signal peptide (e.g., any signal peptide described herein), wherein the introduction results in the treatment of the inner ear disorder in the mammal. In some embodiments, the treatment of an inner ear disorder results in a decrease in severity, frequency, or number of symptoms of the inner ear disorder in a mammal after introduction compared to before introduction (e.g., a decrease of 1% to 100%, or any subrange of this range described herein). In some embodiments, the treatment of any inner ear disorder results in an increase in hearing (e.g., one or more indicators of hearing) in a mammal after introduction compared to before introduction (e.g., an increase of 1% to 400%, or any subrange of this range described herein).

[0263] In some embodiments of any of these methods, the antibody or antigen-binding antibody fragment or soluble VEGF receptor specifically binds to vascular endothelial growth factor (VEGF) (e.g., one or more of VEGF-A, VEGF-B, VEGF-C, and VEGF-D, e.g., one or more of human VEGF-A, human VEGF-B, human VEGF-C, and human VEGF-D). In some embodiments of any of these methods, the AAV vector further comprises one or both of a promoter and a Kozak sequence operably linked to a sequence encoding the antibody or antigen-binding antibody fragment. In some embodiments, wherein the AAV vector comprises a promoter selected from the group consisting of: an inducible promoter, a constitutive promoter, and a tissue-specific promoter. In some embodiments of any of these methods, the AAV vector further comprises a polyadenylation signal sequence. In some embodiments of any of these methods, the mammal is a human. In some embodiments of any of these methods, the mammal (e.g., a human) has been identified as suffering from an inner ear disorder. In some embodiments of any of these methods, the mammal (e.g., a human) has previously been diagnosed as suffering from an inner ear disorder. In some embodiments of any of these methods, the vector comprises a nucleic acid sequence encoding a polypeptide comprising an antibody heavy chain and an antibody light chain. In some embodiments of any of these methods, the vector comprises a nucleic acid sequence encoding an antigen-binding antibody fragment. In some embodiments of any of these methods, the vector comprises a nucleic acid sequence encoding a soluble VEGF receptor operably linked to a signal peptide.

[0264] Also provided herein is a method for reducing VEGF activity (e.g., one or more of VEGF-A, VEGF-B, VEGF-C, and VEGF-D, e.g., one or more of human VEGF-A, human VEGF-B, human VEGF-C, and human VEGF-D) in the inner ear of a mammal in need thereof, the method comprising: introducing into the inner ear of the mammal a therapeutically effective amount of an AAV vector comprising a nucleotide sequence encoding the following polypeptides: (a) a polypeptide comprising an antibody heavy chain variable domain (e.g., any antibody heavy chain variable domain described herein) operably linked to a signal peptide (e.g., any signal peptide described herein) and a polypeptide comprising an antibody light chain variable domain (e.g., any antibody light chain variable domain described herein) operably linked to a signal peptide (e.g., any signal peptide described herein); (b) an antigen-binding antibody fragment (e.g., Fab or scFv) (e.g., any signal peptide described herein) operably linked to a signal peptide (e.g., any signal peptide described herein) Any antigen-binding antibody fragment); or (c) a soluble VEGF receptor (e.g., any soluble VEGF receptor described herein) operably linked to a signal peptide (e.g., any signal peptide described herein), wherein the polypeptide of (a) comprises an antibody that specifically binds to VEGF and reduces VEGF activity, the polypeptide of (b) comprises an antigen-binding antibody fragment that specifically binds to VEGF and reduces VEGF activity, or the soluble VEGF receptor of (c) specifically binds to one or more VEGF proteins and reduces the activity of one or more VEGF proteins; and wherein the introduction results in a decrease (by 1% to 100%, or any sub-range of this range described herein) in the inner ear of the mammal compared to the VEGF activity in the mammal before the introduction (e.g., one or more of VEGF-A, VEGF-B, VEGF-C, and VEGF-D, e.g., one or more of human VEGF-A, human VEGF-B, human VEGF-C, and human VEGF-D). The decrease in VEGF activity in a mammal can be detected using any of the exemplary methods described herein.

[0265] Also provided herein is a method for treating an acoustic neuroma, a vestibular schwannoma, or neurofibromatosis type II (NF2) in the inner ear of a mammal, the method comprising: introducing into the inner ear of the mammal a therapeutically effective amount of an AAV vector, the AAV vector comprising a nucleotide sequence encoding the following polypeptides: (a) a polypeptide comprising an antibody heavy chain variable domain (e.g., any antibody heavy chain variable domain described herein) operably linked to a signal peptide (e.g., any signal peptide described herein) and a polypeptide comprising an antibody light chain variable domain (e.g., any antibody light chain variable domain described herein) operably linked to a signal peptide (e.g., any signal peptide described herein); (b) a polypeptide comprising an antigen-binding antibody fragment (e.g., Fab or scFv) (e.g., any antigen-binding antibody fragment described herein) operably linked to a signal peptide (e.g., any signal peptide described herein); or (c) a soluble VEGF receptor (e.g., any soluble VEGF receptor described herein) operably linked to a signal peptide (e.g., any signal peptide described herein); wherein the polypeptide of (a) (a) encoding an antibody that specifically binds to VEGF (e.g., one or more of VEGF-A, VEGF-B, VEGF-C, and VEGF-D, for example, one or more of human VEGF-A, human VEGF-B, human VEGF-C, and human VEGF-D) and reduces VEGF activity, (b) encoding a polypeptide that specifically binds to VEGF (e.g., one or more of VEGF-A, VEGF-B, VEGF-C, and VEGF-D, for example, one or more of human VEGF-A, human VEGF-B, human VEGF-C, and human VEGF-D) and reduces VEGF activity, or (c) a soluble VEGF receptor that specifically binds to one or more of VEGF-A, VEGF-B, VEGF-C, and VEGF-D (e.g., one or more of human VEGF-A, human VEGF-B, human VEGF-C, and human VEGF-D), and the introduction thereof allows treatment of acoustic neuroma, vestibular schwannoma, or neurofibromatosis type II (NF2) in the inner ear of a mammal. As described herein, successful treatment of one or more of acoustic neuroma, vestibular schwannoma, or neurofibromatosis type II can be detected by observing a decrease in the number, severity, or frequency of one or more symptoms of acoustic neuroma, vestibular schwannoma, or neurofibromatosis type II, respectively, in the mammal, e.g., compared to before the introducing step (e.g., a decrease of 1% to 100%, or any sub-range of this range described herein).

[0266] In some embodiments of any of these methods, the vector comprises a nucleic acid sequence encoding a polypeptide encoding an antibody heavy chain variable domain (e.g., any antibody heavy chain described herein) and an antibody light chain variable domain (e.g., any antibody light chain variable domain described herein). In some embodiments of any of these methods, the vector comprises a nucleic acid sequence encoding a polypeptide comprising an antigen-binding antibody fragment (e.g., any antigen-binding antibody fragment described herein). In some embodiments of any of these methods, the vector comprises a nucleic acid sequence encoding a soluble VEGF receptor (e.g., any soluble VEGF receptor described herein) operably linked to a signal peptide (e.g., any signal peptide described herein). In some embodiments of any of these methods, the AAV vector further comprises one or both of a promoter and a Kozak sequence operably linked to a sequence encoding an antibody or antigen-binding antibody fragment. In some embodiments, the AAV vector comprises a promoter, wherein the promoter is selected from the group consisting of an inducible promoter, a constitutive promoter, or a tissue-specific promoter. In some embodiments, the AAV vector further comprises a polyadenylation signal sequence. In some embodiments of any of these methods, the mammal is a human. In some embodiments of any of these methods, the mammal (e.g., human) has been identified as having an inner ear disorder. In some embodiments of any of these methods, the mammal (e.g., human) has been previously diagnosed as having an inner ear disorder. In some embodiments of any of these methods, the mammal (e.g., human) has been identified or diagnosed as having drug-induced hearing loss. In some embodiments of any of these methods, the mammal (e.g., human) has been identified or diagnosed as having age-related hearing loss.

[0267] In some embodiments, the antibody or antigen-binding fragment thereof comprises an Fc region comprising one or more point mutations that reduce the half-life of the antibody or antigen-binding antibody fragment in vivo.

[0268] In some embodiments of any of these methods, two or more doses of any adeno-associated virus (AAV) vector described herein are introduced or administered into the inner ear of a mammal or subject. Some embodiments of any of these methods may include introducing or administering a first dose of an adeno-associated virus (AAV) vector into the inner ear of a mammal or subject, assessing the hearing function of the mammal or subject after the introduction or administration of the first dose, and administering an additional dose of an adeno-associated virus (AAV) vector to the inner ear of a mammal or subject found to have no hearing function within the normal range (e.g., as determined using any hearing test known in the art).

[0269] In some embodiments of any of the methods described herein, an adeno-associated virus (AAV) vector may be formulated for intracochlear administration. In some embodiments of any of the methods described herein, an adeno-associated virus (AAV) vector described herein may be administered by intracochlear administration or topical administration. In some embodiments of any of the methods described herein, an adeno-associated virus (AAV) vector is administered by use of a medical device (e.g., any exemplary medical device described herein).

[0270] In some embodiments, intracochlear administration can be performed using any method described herein or known in the art. For example, the following surgical technique can be used to administer or introduce an adeno-associated virus (AAV) vector into the cochlea: first visualize using a 0-degree, 2.5 mm rigid endoscope, clean the external auditory canal, and use a round knife to clearly delineate a tympanic flap of about 5 mm. Then, the tympanic flap is raised and moved backward into the middle ear. The chorda tympani nerve is identified and separated, and the scutal bone is removed using a curette to expose the round window membrane. In order to enhance the top distribution of the adeno-associated virus (AAV) vector administered or introduced, a surgical laser can be used to make a 2 mm window in the elliptical window to allow the perilymphatic displacement of the adeno-associated virus (AAV) vector during the round window membrane infusion. Then, a microinfusion device is prepared and brought into the surgical area. The device is moved to the round window, and the tip is placed in the bony round window overhang to allow the microneedle to penetrate the membrane. The pedal is engaged to allow a smooth and stable infusion of the adeno-associated virus (AAV) vector. Then, the device was removed and the round window and stapes footplate were sealed with a gelfoam patch.

[0271] In some embodiments of any of the methods described herein, the subject or mammal is a rodent, non-human primate, or human. In some embodiments of any of the methods described herein, the subject or mammal is an adult, adolescent, teenager, child, toddler, infant, or newborn. In some embodiments of any of the methods described herein, the subject or mammal is 1-5, 1-10, 1-20, 1-30, 1-40, 1-50, 1-60, 1-70, 1-80, 1-90, 1-100, 1-110, 2-5, 2-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-110, 10-30, 10-40, 10-50, 10-60, 10-70, 10-80, 10-90, 10-100, 10-110, 20-40, 20-50, 20-60, 20-70, 20-80, 20-90, 20-100, 20-110, 30-50, 30-60, 30-70, 30-80, 30-90, 30-100, 40-60, 40-70, 40-80, 40-90, 40-100, 50-70, 50-80, 50-90, 50-100, 60-80, 60-90, 60-100, 70-90, 70-100, 70-110, 80-100, 80-110 or 90-110 years old. In some embodiments of any of the methods described herein, the subject or mammal is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 months old.

[0272] In some embodiments of any of the methods described herein, the subject or mammal has or is at risk of developing hearing loss (eg, drug-induced hearing loss).

[0273] In some embodiments of any of the methods described herein, the subject or mammal has been previously identified as having a VEGF gene mutation.

[0274] In some embodiments, any conventional functional hearing test known in the art can be used to determine the successful treatment of hearing loss (e.g., drug-induced hearing loss) in a subject. Non-limiting examples of functional hearing tests are various types of audiometry (e.g., pure tone tests, speech tests, middle ear tests, auditory brainstem responses, and otoacoustic emissions).

[0275] Methods for introducing any of the adeno-associated viral (AAV) vectors described herein into mammalian cells are known in the art (eg, by lipofection or by using a viral vector, eg, any of the viral vectors described herein).

[0276] Pharmaceutical compositions and kits

[0277] In some embodiments, any composition described herein may further include one or more agents (e.g., liposomes or cationic lipids) that facilitate entry of nucleic acids or any vector described herein into mammalian cells. In some embodiments, natural and / or synthetic polymers may be used to formulate any vector described herein. Non-limiting examples of polymers that may be included in any composition described herein may include, but are not limited to, DYNAMIC (Arrowhead Research Corp., Pasadena, Calif.), formulations from Mirus Bio (Madison, Wis.) and Roche Madison (Madison, Wis.), PhaseRX polymer formulations such as, but not limited to, SMARTT POLYMER (PhaseRX, Seattle, Wash.), DMRI / DOPE, poloxamer, from Vical (San Diego, Calif.) Adjuvants, chitosan, cyclodextrins from Calando Pharmaceuticals (Pasadena, Calif.), dendrimers and poly(lactic-co-glycolic acid) (PLGA) polymers, RONDEL TM (RNAi / oligonucleotide nanoparticle delivery) polymers (Arrowhead Research Corporation, Pasadena, Calif.), and pH-responsive co-block polymers such as, but not limited to, those produced by PhaseRX (Seattle, Wash.). Many of these polymers have demonstrated efficacy in delivering oligonucleotides to mammalian cells in vivo (see, e.g., deFougerolles, Human Gene Ther. 19:125-132, 2008; Rozema et al., Proc. Natl. Acad. Sci. USA 104:12982-12887, 2007; Rozema et al., Proc. Natl. Acad. Sci. USA 104:12982-12887, 2007; Hu-Lieskovan et al., Cancer Res. 65:8984-8982, 2005; Heidel et al., Proc. Natl. Acad. Sci. USA 104:5715-5721, 2007).

[0278] Any composition described herein can be, for example, a pharmaceutical composition. A pharmaceutical composition can include any composition described herein and one or more pharmaceutically or physiologically acceptable carriers, diluents, or excipients. Such compositions can include one or more buffers, such as neutral buffered saline, phosphate buffered saline, etc.; one or more carbohydrates, such as glucose, mannose, sucrose, and dextran; mannitol; one or more proteins, polypeptides, or amino acids, such as glycine; one or more antioxidants; one or more chelating agents, such as EDTA or glutathione; and / or one or more preservatives.

[0279] In some embodiments, the composition includes a pharmaceutically acceptable carrier (e.g., phosphate buffered saline, saline or bacteriostatic water). When formulated, the solution will be administered in a manner compatible with the dosage formulation and in a therapeutically effective amount. The formulation is easily administered in a variety of dosage forms such as injectable solutions, injectable gels, drug release capsules, etc.

[0280] As used herein, the term "pharmaceutically acceptable carrier" includes solvents, dispersion media, coatings, antibacterial agents, antifungal agents, etc., that are compatible with pharmaceutical administration. Supplementary active compounds may also be incorporated into any of the compositions described herein.

[0281] In some embodiments, a single dose of any of the compositions described herein may include, for example, at least 1 ng, at least 2 ng, at least 4 ng, about 6 ng, about 8 ng, at least 10 ng, at least 20 ng, at least 30 ng, at least 40 ng, at least 50 ng, at least 60 ng, at least 70 ng, at least 80 ng, at least 90 ng, at least 100 ng, at least 200 ng, at least 300 ng, at least 400 ng, at least 500 ng, at least 1 μg, at least 2 μg, at least 4 μg, at least 6 μg, at least 8 μg, at least 10 μg, at least 12 μg, at least 14 μg, at least 16 μg, at least 18 μg, at least 19 μg, at least 20 μg, at least 21 μg, at least 22 μg, at least 23 μg, at least 24 μg, at least 25 μg, at least 26 μg, at least 27 μg, at least 28 μg, at least 29 μg, at least 30 μg, at least 31 μg, at least 32 μg, at least 33 μg, at least 34 μg, at least 35 μg, at least 36 μg, at least 37 μg, at least 38 μg, at least 39 μg, at least 40 μg, 20μg, at least 22μg, at least 24μg, at least 26μg, at least 28μg, at least 30μg, at least 32μg, at least 34μg, at least 36μg, at least 38μg, at least 40μg, at least 42μg, at least 44μg, at least 46μg, at least 48μg, at least 50μg, at least 52μg, at least 54μg, at least 56μg, at least 58μg, at least 60μg, at least 62μg, at least 64μg, at least 66μg, at least 68μg, at least 70μg, at least 72μg, at least 74μg, at least 76μg, at least 78μg, at least 80μg, at least 82μg, at least 84μg, at least 86 , at least 120 μg, at least 122 μg, at least 124 μg, at least 126 μg, at least 128 μg, at least 130 μg, at least 132 μg, at least 134 μg, at least 136 μg, at least 138 μg, at least 140 μg, at least 142 μg, at least 144 μg, at least 146 μg, at least 148 μg, at least 150 μg, at least 152 μg, at least 154 μg, at least 156 μg, at least 158 ​​μg, at least 159 μg, at least 160 μg, at least 161 μg, at least 162 μg, at least 163 μg, at least 164 μg, at least 165 μg or at least 200 μg of the total amount of at least two different carriers.

[0282] The compositions provided herein can, for example, be formulated to be compatible with their intended route of administration.A non-limiting example of an intended route of administration is topical administration (eg, intracochlear administration).

[0283] In some embodiments, the therapeutic composition is formulated to include lipid nanoparticles. In some embodiments, the therapeutic composition is formulated to include polymer nanoparticles. In some embodiments, the therapeutic composition is formulated to include minicircle DNA. In some embodiments, the therapeutic composition is formulated to include CELiD DNA. In some embodiments, the therapeutic composition is formulated to include synthetic perilymph. Exemplary synthetic perilymph includes 20-200mM NaCl; 1-5mM KCl; 0.1-10mM CaCl2; 1-10mM glucose; 2-50mM HEPES, with a pH between about 6 and about 9.

[0284] Also provided are kits comprising any of the compositions described herein. In some embodiments, the kit may include a solid composition (e.g., a lyophilized composition comprising at least two different carriers described herein) and a liquid for dissolving the lyophilized composition. In some embodiments, the kit may include a preloaded syringe comprising any of the compositions described herein.

[0285] In some embodiments, a kit includes a vial containing any of the compositions described herein (eg, formulated as an aqueous composition, eg, an aqueous pharmaceutical composition).

[0286] In some embodiments, the kits can include instructions for performing any of the methods described herein.

[0287] Devices and surgical methods

[0288] Provided herein are therapeutic delivery systems for treating hearing loss (e.g., acoustic neuroma / vestibular schwannoma and related hearing loss). In one aspect, the therapeutic delivery system comprises i) a medical device capable of creating one or more incisions in the round window membrane of the inner ear of a human subject in need thereof, and ii) an effective dose of a composition (e.g., any composition described herein). In some embodiments, the medical device comprises a plurality of microneedles.

[0289] Also provided herein are surgical methods for treating hearing loss (e.g., acoustic neuroma / vestibular schwannoma and related hearing loss). In some embodiments, the method comprises the following steps: introducing a first incision into the cochlea of ​​a human subject at a first incision point; and administering a therapeutically effective amount of any composition provided herein within the cochlea. In some embodiments, the composition is applied to the subject at the first incision point. In some embodiments, the composition is applied to the subject in or through the first incision.

[0290] In some embodiments of any method described herein, any composition described herein is applied to or through the cochlear oval window membrane of the subject. In some embodiments of any method described herein, any composition described herein is applied to or through the cochlear round window membrane of the subject. In some embodiments of any method described herein, a medical device capable of producing multiple incisions in the round window membrane is used to apply the composition. In some embodiments, the medical device includes a plurality of microneedles. In some embodiments, the medical device includes a plurality of microneedles of a generally circular first aspect, wherein each microneedle has a diameter of at least about 10 microns. In some embodiments, the medical device includes a base and / or a reservoir capable of accommodating the composition. In some embodiments, the medical device includes a plurality of hollow microneedles, each of which includes a cavity capable of transferring the composition. In some embodiments, the medical device includes a device for generating at least a partial vacuum.

[0291] The present invention is further described in detail by reference to the following experimental examples. Unless otherwise indicated, these examples are provided for illustrative purposes only and are not intended to be limiting. Therefore, the present invention should never be interpreted as being limited to the following examples, but should be interpreted as covering any and all variations that become apparent due to the teachings provided herein.

[0292] Without further description, it is believed that one of ordinary skill in the art can use the foregoing description and the following illustrative examples to prepare and utilize the compositions of the present invention and practice the claimed methods. The following working examples particularly point out various aspects of the present invention and should not be construed as limiting the remainder of the disclosure in any way.

[0293] Example

[0294] Example 1. Construction of viral vector

[0295] Four different recombinant AAV vectors were generated and Figure 1A -D is shown.

[0296] Figure 1A The vector in is an exemplary AAV vector of 4474 bp (SEQ ID NO: 35), which includes the following subsequences in the 5' to 3' direction:

[0297] CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCTGCGGCCGCACGCGT(5’ITR;SEQ ID NO:36);

[0298]

[0299] CTCCTGGGCAACGTGCTGGTTATTGTGACCGGTGCCACC (spacer; SEQ ID NO: 38);

[0300] ATGTACCGGATGCAGCTGCTGAGCTGTATCGCCCTGTCTCT GGCCCTGGTCACCAATTCT (IL-2 secretion signal sequence; SEQ ID NO: 39);

[0301]

[0302] CGGAAGAGAAGA (Linker sequence; SEQ ID NO:41);

[0303] GGCTCTGGCGAAGGCAGAGGCAGCCTGCTTACATGTGGCGACGTGGAAGAGAACCCCGGACCT (T2A sequence; SEQ ID NO:42);

[0304] ATGTATAGAATGCAGCTCCTGTCCTGCATTGCCCTGAGCCTGGCTCTCGTGACCAACAGC (IL-2 secretion signal sequence; SEQ ID NO:43);

[0305] GACATCCAGATGACACAGAGCCCCAGCAGCCTGTCTGCCTCTGTGGGAGACAGAGTGACCATCACCTGTAGCGCCAGCCAGGACATCTCCAACTACCTGAACTGGTATCAGCAAAAGCCCGGCAAGGCCCCTAAGGTGCTGATCTACTTCACAAGCAGCCTGCACTCCGGCGTGCCCAGCAGATTTTCTGGCTCTGGCAGCGGCACCGACTTCACCCTGACCATATCTAGCCTGCAGCCTGAGGACTTCGCCACCTACTACTGCCAGCAGTACAGCACCGTGCCTTGGACATTTGGCCAGGGCACAAAGGTGGAAATCAAGCGGACTGTGGCCGCTCCTAGCGTGTTCATCTTTCCACCTAGCGACGAGCAGCTGAAGTCTGGCACAGCCTCTGTCGTGTGCCTGCTGAACAACTTCTACCCCAGAGAAGCCAAGGTGCAGTGGAAAGTGGACAATGCCCTGCAGAGCGGCAACAGCCAAGAGAGCGTGACAGAGCAGGACTCCAAGGATAGCACCTATAGCCTGAGCAGCACCCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAAGTGTACGCCTGCGAAGTGACCCACCAGGGCCTTTCTAGCCCTGTGACCAAGAGCTTCAACCGGGGCGAATGTTAA (Sequence encoding the light chain of bevacizumab; SEQ ID NO:44);

[0306] GAGCTCGCTGATCAGCCTCGA (linker sequence; SEQ ID NO: 45);

[0307] CTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGG (bovine growth hormone polyA tail sequence; SEQ ID NO:46);

[0308] AAGCTTGAATTCAGCTGACGTGCCTCGGACCGCT (linker sequence; SEQ ID NO: 47); and

[0309] AGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGCTGCCTGCAGG (3'ITR; SEQ ID NO: 48).

[0310] The IL-2 signal sequence encoded by each of SEQ ID NOs: 39 and 43 is MYRMQLLSCIALSLALVTNS (SEQ ID NO: 49). The T2A sequence encoded by SEQ ID NO: 42 is GSGEGRGSLLTCGDVEENPGP (SEQ ID NO: 50). SEQ ID NO: 40 encodes the heavy chain of bevacizumab (SEQ ID NO: 6). SEQ ID NO: 44 encodes the light chain of bevacizumab (SEQ ID NO: 5). The last three nucleotides in SEQ ID NO: 44 are stop codons.

[0311] Figure 1B The vector in is an exemplary AAV vector of 3814 bp (SEQ ID NO: 51), which includes the following subsequences in the 5' to 3' direction:

[0312] CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCTGCGGCCGCACGCGT(3’ITR;SEQ ID NO:36);

[0313]

[0314] CTCCTGGGCAACGTGCTGGTTATTGTGACCGGTGCCACC (Adapter sequence; SEQ ID NO:38);

[0315] ATGTACCGGATGCAGCTGCTGAGCTGTATCGCCCTGTCTCT GGCCCTGGTCACCAATTCT (IL-2 secretion signal sequence; SEQ ID NO:39);

[0316] GAGGTGCAGCTGGTGGAATCTGGCGGCGGACTTGTTCAACCTGGCGGCTCTCTGAGACTGAGCTGTGCCGCTTCTGGCTACGACTTCACCCACTACGGCATGAACTGGGTCCGACAGGCCCCTGGCAAAGGCCTTGAATGGGTCGGATGGATCAACACCTACACCGGCGAGCCAACATACGCCGCCGACTTCAAGCGGAGATTCACCTTCAGCCTGGACACCAGCAAGAGCACCGCCTACCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGCGCCAAGTATCCCTACTACTACGGCACCAGCCACTGGTACTTTGACGTGTGGGGACAGGGCACACTGGTCACAGTGTCTAGCGCCTCTACAAAGGGCCCCAGCGTTTTCCCACTGGCTCCTAGCAGCAAGTCTACCAGCGGAGGAACAGCCGCTCTGGGCTGTCTGGTCAAGGACTACTTTCCCGAGCCTGTGACCGTGTCCTGGAATTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCTGTGCTGCAAAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCAAGCAGCTCTCTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGACAAGACCCACACCGGCAAG (Sequence encoding the heavy chain of ranibizumab; SEQ ID NO:52);

[0317] CGGAAGAGAAGA (Linker sequence; SEQ ID NO:41);

[0318] GGCTCTGGCGAAGGCAGAGGCAGCCTGCTTACATGTGGCG ACGTGGAAGAGAACCCCGGACCT (T2A sequence; SEQ ID NO:42);

[0319] ATGTATAGAATGCAGCTCCTGTCCTGCATTGCCCTGAGCCT GGCTCTCGTGACCAACAGC (IL-2 signal secretion sequence; SEQ ID NO:43);

[0320] GACATCCAGCTGACACAGAGCCCCAGCAGCCTGTCTGCCTCTGTGGGAGACAGAGTGACCATCACCTGTAGCGCCAGCCAGGACATCTCCAACTACCTGAACTGGTATCAGCAAAAGCCCGGCAAGGCCCCTAAGGTGCTGATCTACTTCACAAGCAGCCTGCACTCCGGCGTGCCCAGCAGATTTTCTGGCTCTGGCAGCGGCACCGACTTCACCCTGACCATATCTAGCCTGCAGCCTGAGGACTTCGCCACCTACTACTGCCAGCAGTACAGCACCGTGCCTTGGACATTTGGCCAGGGCACAAAGGTGGAAATCAAGCGGACTGTGGCCGCTCCTAGCGTGTTCATCTTTCCACCTAGCGACGAGCAGCTGAAGTCTGGCACAGCCTCTGTCGTGTGCCTGCTGAACAACTTCTACCCCAGAGAAGCCAAGGTGCAGTGGAAAGTGGACAATGCCCTGCAGAGCGGCAACAGCCAAGAGAGCGTGACAGAGCAGGACTCCAAGGATAGCACCTATAGCCTGAGCAGCACCCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAAGTGTACGCCTGCGAAGTGACCCACCAGGGCCTTTCTAGCCCTGTGACCAAGAGCTTCAACCGGGGCGAATGTTAA (Sequence encoding the light chain of ranibizumab; SEQ ID NO:53).

[0321] GAGCTCGCTGATCAGCCTCGA (Adapter sequence; SEQ ID NO: 45);

[0322] CTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGG (Bovine growth hormone polyA tail sequence; SEQ ID NO: 46); and

[0323] AAGCTTGAATTCAGCTGACGTGCCTCGGACCGCT (Adapter; SEQ ID NO: 47);

[0324] AGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGCTGCCTGCAGG (SEQID NO: 48).

[0325] The IL-2 signal sequence encoded by each of SEQ ID NOs: 39 and 43 is MYR MQLLSCIALSLALVTNS (SEQ ID NO: 49). The T2A sequence encoded by SEQ ID NO: 42 is GSGEGRGSLLTCGDVEENPGP (SEQ ID NO: 50). SEQ ID NO: 52 encodes the heavy chain of ranibizumab (EVQLVESGGGLVQPGGS LRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTGK; SEQ ID NO: 54). SEQ ID NO: 53 encodes the light chain of bevacizumab (SEQ ID NO: 7). The last three nucleotides in SEQ ID NO: 53 are stop codons.

[0326] Figure 1C An exemplary AAV vector of 4573 bp (SEQ ID NO: 55) includes the following subsequences in the 5' to 3' direction:

[0327] CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCTGCGGCCGCACGCGT (5'ITR; SEQ ID NO: 36);

[0328]

[0329] CTCCTGGGCAACGTGCTGGTTATTGTGACCGGTGCCACC (Adapter sequence; SEQ ID NO:38);

[0330] ATGTACCGGATGCAGCTGCTGAGCTGTATCGCCCTGTCTCT GGCCCTGGTCACCAATTCT (IL-2 secretion signal sequence; SEQ ID NO:39);

[0331] GAGGTGCAGCTGGTGGAATCTGGCGGCGGACTTGTTCAACCTGGCGGCTCTCTGAGACTGAGCTGTGCCGCTTCTGGCTACGACTTCACCCACTACGGCATGAACTGGGTCCGACAGGCCCCTGGCAAAGGCCTTGAATGGGTCGGATGGATCAACACCTACACCGGCGAGCCAACATACGCCGCCGACTTCAAGCGGAGATTCACCTTCAGCCTGGACACCAGCAAGAGCACCGCCTACCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGCGCCAAGTATCCCTACTACTACGGCACCAGCCACTGGTACTTTGACGTGTGGGGACAGGGCACACTGGTCACAGTGTCTAGCGCCTCTACAAAGGGCCCCAGCGTTTTCCCACTGGCTCCTAGCAGCAAGTCTACCAGCGGAGGAACAGCCGCTCTGGGCTGTCTGGTCAAGGACTACTTTCCCGAGCCTGTGACCGTGTCCTGGAATTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCTGTGCTGCAAAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCAAGCAGCTCTCTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGACAAGACCCACACCGGCAAG (Sequence encoding the heavy chain of ranibizumab; SEQ ID NO:52);

[0332] CGGAAGAGAAGA (Linker sequence; SEQ ID NO:41);

[0333] GGCTCTGGCGAAGGCAGAGGCAGCCTGCTTACATGTGGCG ACGTGGAAGAGAACCCCGGACCT (T2A sequence; SEQ ID NO:42);

[0334] ATGTATAGAATGCAGCTCCTGTCCTGCATTGCCCTGAGCCT GGCTCTCGTGACCAACAGC (IL-2 signal secretion sequence; SEQ ID NO:43);

[0335] GACATCCAGCTGACACAGAGCCCCAGCAGCCTGTCTGCCTCTGTGGGAGACAGAGTGACCATCACCTGTAGCGCCAGCCAGGACATCTCCAACTACCTGAACTGGTATCAGCAAAAGCCCGGCAAGGCCCCTAAGGTGCTGATCTACTTCACAAGCAGCCTGCACTCCGGCGTGCCCAGCAGATTTTCTGGCTCTGGCAGCGGCACCGACTTCACCCTGACCATATCTAGCCTGCAGCCTGAGGACTTCGCCACCTACTACTGCCAGCAGTACAGCACCGTGCCTTGGACATTTGGCCAGGGCACAAAGGTGGAAATCAAGCGGACTGTGGCCGCTCCTAGCGTGTTCATCTTTCCACCTAGCGACGAGCAGCTGAAGTCTGGCACAGCCTCTGTCGTGTGCCTGCTGAACAACTTCTACCCCAGAGAAGCCAAGGTGCAGTGGAAAGTGGACAATGCCCTGCAGAGCGGCAACAGCCAAGAGAGCGTGACAGAGCAGGACTCCAAGGATAGCACCTATAGCCTGAGCAGCACCCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAAGTGTACGCCTGCGAAGTGACCCACCAGGGCCTTTCTAGCCCTGTGACCAAGAGCTTCAACCGGGGCGAATGT (Sequence encoding the light chain of ranibizumab; SEQ ID NO:56);

[0336] GGCTCCGGAGAGGGCAGAGGAAGTCTGCTAACATGCGGT GACGTCGAGGAGAATCCTGGCCCA (Adapter sequence; SEQ ID NO:57);

[0337] ATGGAGAGCGACGAGAGCGGCCTGCCCGCCATGGAGATCGAGTGCCGCATCACCGGCACCCTGAACGGCGTGGAGTTCGAGCTGGTGGGCGGCGGAGAGGGCACCCCCGAGCAGGGCCGCATGACCAACAAGATGAAGAGCACCAAAGGCGCCCTGACCTTCAGCCCCTACCTGCTGAGCCACGTGATGGGCTACGGCTTCTACCACTTCGGCACCTACCCCAGCGGCTACGAGAACCCCTTCCTGCACGCCATCAACAACGGCGGCTACACCAACACCCGCATCGAGAAGTACGAGGACGGCGGCGTGCTGCACGTGAGCTTCAGCTACCGCTACGAGGCCGGCCGCGTGATCGGCGACTTCAAGGTGATGGGCACCGGCTTCCCCGAGGACAGCGTGATCTTCACCGACAAGATCATCCGCAGCAACGCCACCGTGGAGCACCTGCACCCCATGGGCGATAACGATCTGGATGGCAGCTTCACCCGCACCTTCAGCCTGCGCGACGGCGGCTACTACAGCTCCGTGGTGGACAGCCACATGCACTTCAAGAGCGCCATCCACCCCAGCATCCTGCAGAACGGGGGCCCCATGTTCGCCTTCCGCCGCGTGGAGGAGGATCACAGCAACACCGAGCTGGGCATCGTGGAGTACCAGCACGCCTTCAAGACCCCGGATGCAGATGCCGGTGAAGAATAA (Sequence encoding TurboGFP; SEQ ID NO:58);

[0338] GAGCTCGCTGATCAGCCTCGA (Adapter sequence; SEQ ID NO:45);

[0339] CTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGG (Bovine growth hormone polyA tail sequence; SEQ ID NO:46);

[0340] AAGCTTGAATTCAGCTGACGTGCCTCGGACCGCT (Adapter sequence; SEQ ID NO:47); and

[0341] AGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGCTGCCTGCAGG (3’ ITR; SEQ ID NO:48).

[0342] The IL-2 signal sequence encoded by each of SEQ ID NOs: 39 and 43 is MYR MQLLSCIALSLALVTNS (SEQ ID NO: 49). The T2A sequence encoded by SEQ ID NO: 42 is GSGEGRGSLLTCGDVEENPGP (SEQ ID NO: 50). SEQ ID NO: 52 encodes the heavy chain of ranibizumab (SEQ ID NO: 54). SEQ ID NO: 56 encodes the light chain of bevacizumab (SEQ ID NO: 7). SEQ ID NO: 58 encodes TurboGFP (MESDESGLPAMEIECRITGTLNGVEFELVGGGEGTPEQGRMTNKMKSTKGALTFSPYLLSHVMGYGFYHFGTYPSGYENPFLHAINNGGYTNTRIEKYEDGGVLHVSFSYRYEAGRVIGDFKVMGTGFPEDSVIFTDKIIRSNATVEHLHPMGDNDLDGSFTRTFSLRDGGYYSSVVDSHMHFKSAIHPSILQNGGPMFAFRRVEEDHSNTELGIVEYQHAFKTPDADAGEE; SEQ ID NO: 59). The last three nucleotides in SEQ ID NO: 58 are stop codons.

[0343] Figure 1D An exemplary AAV vector of 3631 bp (SEQ ID NO: 60) includes the following subsequences in the 5' to 3' direction:

[0344] CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCTGCGGCCGCACGCGT (5'ITR; SEQ ID NO: 36);

[0345]

[0346] CTCCTGGGCAACGTGCTGGTTATTGTGACCGGTGCCACC (spacer; SEQ ID NO: 38);

[0347] ATGTACCGGATGCAGCTGCTGAGCTGTATCGCCCTGTCTCT GGCCCTGGTCACCAATTCT (IL-2 secretion signal sequence; SEQ ID NO: 39);

[0348]

[0349] GAGCTCGCTGATCAGCCTCGA (linker sequence; SEQ ID NO: 45);

[0350] CTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGG (bovine growth hormone polyA tail sequence; SEQ ID NO:46);

[0351] AAGCTTGAATTCAGCTGACGTGCCTCGGACCGCT (linker sequence; SEQ ID NO: 47); and

[0352] AGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGCTGCCTGCAGG (3'ITR; SEQ ID NO: 48).

[0353] The IL-2 signal sequence encoded by SEQ ID NO:39 is MYRMQLLSCIALSLALVTNS (SEQ ID NO:49). SEQ ID NO:61 encodes aflibercept (SEQ ID NO:12). The last three nucleotides in SEQ ID NO:61 are stop codons.

[0354] In order to determine the Figures 1A-1C For the AAV vector-driven protein expression shown in Figure 2, HEK293FT cells were plated at 7 x 10 4 cells / well (400 μL per well) were seeded overnight. Figures 1A-1D The AAV vector shown in Figure 2 was used to transfect HEK293FT cells (for generation of Figure 2HEK293FT cells were also plated at 4 x 10 in the presence of 2 μM etoposide in wells of a 96-well plate. 4 Cells / well (50 μL per well) were seeded for six hours (for generation Figure 2 The data in lanes 6-8 and 14-16 of Figure 1A The AAV vectors shown in Figure 1 were added to the culture medium at a multiplicity of infection (MOI) of 7.5 x 10 4 , 2.2x 10 5 or 5.5x 10 5 Supernatants were harvested from wells 72 h after treatment and cultured in the presence of Figure 2 Lanes 2-8) and non-reducing conditions ( Figure 2 The samples were loaded onto 4%-12% Bolt protein gels in lanes 10-16 of the flow cytometry. Anti-ranibizumab antibody detecting the Fab region was used as the primary antibody, and anti-human IgG was used as the secondary antibody.

[0355] like Figure 2 As shown, heavy and light chain ranibizumab were detected in lanes 3 and 6-8, and intact ranibizumab (heterodimer) was detected in lanes 11 and 14-16.

[0356] Example 2. Binding activity of anti-human VEGF monoclonal antibodies

[0357] A series of experiments were conducted to determine the Figure 1A Binding activity of bevacizumab produced in HEK293FT cells after transfection with the indicated AAV vectors. A first set of control experiments was performed to calibrate the plasmon surface resonance instrument using recombinant human VEGF as a binding agent (using either VEGF in buffer or in conditioned medium (respectively)). Figure 3A and Figure 3B A second set of experiments was performed to measure the expression of control conditioned medium and medium treated with Figure 1A The human VEGF binding activity of the conditioned medium of HEK293TF cells transfected with the indicated AAV vectors (respectively Figure 4A and 4B ).

[0358] Prepare the samples in a 384-well sample plate by diluting 1:10 in 1x kinetic buffer (Fortebio, 18-1105). Figure 1ASamples of bevacizumab in culture medium or conditioned medium of HEK293TF cells transfected with the indicated AAV vectors. Anti-hVEGF MmAb (R&D, MAB293-100) was diluted at a concentration of 10 μg / mL as a positive control. The capture agent, recombinant human VEGF (R&D, 293-VE-010) was diluted from 200 nM to 3.125 nM in a 1:2 serial dilution ratio.

[0359] exist The binding affinity of conditioned media samples to mouse anti-human VEGF antibody (R&D) samples was measured in 1x kinetic buffer in the HTX biosensor instrument. Binding characteristics and K D Value by The analysis software DataAnalysis HT10.0 was used. Figure 3A -B, K of anti-hVEGF MmAb in buffer D <1.0x 10 -12 M, and the anti-hVEGF MmAb in the conditioned medium was <1.0 x 10 -12 M. The conditioned medium itself has no binding affinity and the intensity is very low (only background signal) ( Figure 4A ). In contrast, Figure 1A Conditioned medium from HEK293TF cells transfected with the indicated AAV vectors produced bevacizumab with high binding affinity but low potency ( Figure 4B ; K D <1.0x 10 -12 M). Figure 4C shows the loading of the sample and the corresponding K D , K D Error, equilibrium association constant (k a ) and dissociation (k dis ) and k dis Error table.

[0360] In summary, the anti-hVEGF mouse antibody (R&D) showed high binding affinity (K D Less than 1.0x 10 -12 M). Bevacizumab conditioned medium samples showed high binding affinity (K D The K values ​​could not be inferred from the binding data of the control conditioned medium samples. D value.

[0361] Taken together, these data show that the AAV vectors provided herein can result in the expression and secretion of anti-VEGF antibodies and can be used to express anti-VEGF antibodies in the inner ear of mammals.

[0362] Other Implementations

[0363] It should be understood that although the invention has been described in conjunction with the detailed description of the invention, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages and modifications are within the scope of the appended claims.

[0364] All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the event of a conflict, the present specification (including definitions) will prevail. The section headings and any descriptions of materials, methods, and examples are illustrative only and are not intended to be limiting.

[0365] The present application further relates to the following embodiments.

[0366] 1. A method comprising introducing a therapeutically effective amount of an adeno-associated virus (AAV) vector into the inner ear of a mammal, wherein the adeno-associated virus (AAV) vector comprises a nucleotide sequence encoding the following polypeptide:

[0367] (a) a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide; or

[0368] (b) A polypeptide comprising an antigen-binding antibody fragment operably linked to a signal peptide.

[0369] 2. A method for increasing the level of an antibody or antigen-binding antibody fragment in the inner ear of a mammal in need thereof, the method comprising:

[0370] A therapeutically effective amount of an AAV vector is introduced into the inner ear of the mammal, wherein the AAV vector comprises a nucleotide sequence encoding the following polypeptide:

[0371] (a) a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide; or

[0372] (b) a polypeptide comprising an antigen-binding antibody fragment linked to a signal peptide;

[0373] wherein said introducing results in increased levels of said antibody or antigen-binding antibody fragment in the inner ear of said mammal.

[0374] 3. The method of embodiment 1 or 2, wherein the antibody or the antigen-binding antibody fragment specifically binds to vascular endothelial growth factor (VEGF).

[0375] 4. The method of embodiment 3, wherein the antibody or antigen-binding antibody fragment reduces VEGF activity.

[0376] 5. A method as described in any of embodiments 1-4, wherein the AAV vector further comprises one or both of a promoter and a Kozak sequence operably linked to a sequence encoding the antibody or the antigen-binding antibody fragment.

[0377] 6. The method of embodiment 5, wherein the AAV vector comprises a promoter selected from the group consisting of an inducible promoter, a constitutive promoter, and a tissue-specific promoter.

[0378] 7. The method of any one of embodiments 1-6, wherein the AAV vector further comprises a polyadenylation signal sequence.

[0379] 8. The method of any one of embodiments 1-7, wherein the mammal is a human.

[0380] 9. The method of any one of embodiments 1-8, wherein the mammal has been identified as having an inner ear disorder.

[0381] 10. The method of any one of embodiments 1-8, wherein the mammal has been diagnosed with an inner ear disorder.

[0382] 11. A method as described in any of embodiments 1-10, wherein the AAV vector comprises a nucleic acid sequence encoding the following polypeptides: a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide.

[0383] 12. The method of any one of embodiments 1-10, wherein the AAV vector comprises a nucleic acid sequence encoding a polypeptide comprising an antigen-binding antibody fragment operably linked to a signal.

[0384] 13. A method for treating an inner ear disorder in a mammal in need thereof, the method comprising:

[0385] A therapeutically effective amount of an AAV vector is introduced into the inner ear of the mammal, wherein the AAV vector comprises a nucleotide sequence encoding the following polypeptide:

[0386] (a) a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide; or

[0387] (b) a polypeptide comprising an antigen-binding antibody fragment linked to a signal peptide;

[0388] wherein said introducing results in said inner ear disorder being treated in said mammal.

[0389] 14. A method as described in embodiment 13, wherein the AAV vector further comprises one or both of a promoter and a Kozak sequence operably linked to a sequence encoding the antibody or the antigen-binding antibody fragment.

[0390] 15. The method of embodiment 14, wherein the AAV vector comprises a promoter selected from the group consisting of an inducible promoter, a constitutive promoter, and a tissue-specific promoter.

[0391] 16. The method of any one of embodiments 13-15, wherein the AAV vector further comprises a polyadenylation signal sequence.

[0392] 17. The method of any one of embodiments 13-16, wherein the mammal is a human.

[0393] 18. The method of any one of embodiments 13-17, wherein the mammal has been identified as having an inner ear disorder.

[0394] 19. The method of any one of embodiments 13-17, wherein the mammal has been diagnosed with an inner ear disorder.

[0395] 20. A method as described in any of embodiments 13-19, wherein the AAV vector comprises a nucleic acid sequence encoding the following polypeptides: a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide.

[0396] 21. The method of any one of embodiments 13-19, wherein the AAV vector comprises a nucleic acid sequence encoding a polypeptide comprising an antigen-binding antibody fragment operably linked to a signal.

[0397] 22. A method of reducing VEGF activity in the inner ear of a mammal in need thereof, the method comprising:

[0398] A therapeutically effective amount of an AAV vector is introduced into the inner ear of the mammal, wherein the AAV vector comprises a nucleotide sequence encoding the following polypeptide:

[0399] (a) a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide; or

[0400] (b) a polypeptide comprising an antigen-binding antibody fragment linked to a signal peptide;

[0401] The polypeptide of (a) encodes an antibody that specifically binds to VEGF and reduces VEGF activity, and the polypeptide of (b) encodes an antigen-binding antibody fragment that specifically binds to VEGF and reduces VEGF activity;

[0402] wherein said introducing results in a decrease in VEGF activity in the inner ear of said mammal.

[0403] 23. A method as described in embodiment 22, wherein the AAV vector further comprises one or both of a promoter and a Kozak sequence operably linked to a sequence encoding the antibody or the antigen-binding antibody fragment.

[0404] 24. The method of embodiment 23, wherein the AAV vector comprises a promoter selected from the group consisting of an inducible promoter, a constitutive promoter, and a tissue-specific promoter.

[0405] 25. The method of any one of embodiments 22-24, wherein the AAV vector further comprises a polyadenylation signal sequence.

[0406] 26. The method of any one of embodiments 22-25, wherein the mammal is a human.

[0407] 27. The method of any one of embodiments 22-26, wherein the mammal has been identified or diagnosed as having an acoustic neuroma.

[0408] 28. The method of any one of embodiments 22-26, wherein the mammal has been identified or diagnosed as having a vestibular schwannoma.

[0409] 29. The method of any one of embodiments 22-26, wherein the mammal has been identified or diagnosed as having neurofibromatosis type 2.

[0410] 30. A method as described in any of embodiments 22-29, wherein the AAV vector comprises a nucleic acid sequence encoding the following polypeptides: a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide.

[0411] 31. A method as described in any of embodiments 22-29, wherein the AAV vector comprises a nucleic acid sequence encoding the following polypeptide: a polypeptide comprising an antigen-binding antibody fragment operably linked to a signal peptide.

[0412] 32. A method of treating an acoustic neuroma, a vestibular schwannoma, or neurofibromatosis type 2 in the inner ear of a mammal, the method comprising:

[0413] A therapeutically effective amount of an AAV vector is introduced into the inner ear of the mammal, wherein the AAV vector comprises a nucleotide sequence encoding the following polypeptide:

[0414] (a) a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide; or

[0415] (b) a polypeptide comprising an antigen-binding antibody fragment linked to a signal peptide;

[0416] The polypeptide of (a) encodes an antibody that specifically binds to VEGF and reduces VEGF activity, and the polypeptide of (b) encodes an antigen-binding antibody fragment that specifically binds to VEGF and reduces VEGF activity;

[0417] wherein said introducing results in treatment of an acoustic neuroma, a vestibular schwannoma or neurofibromatosis type II, respectively, in the inner ear of said mammal.

[0418] 33. A method as described in embodiment 32, wherein the AAV vector further comprises one or both of a promoter and a Kozak sequence operably linked to a sequence encoding the antibody or the antigen-binding antibody fragment.

[0419] 34. The method of embodiment 33, wherein the AAV vector comprises a promoter selected from the group consisting of an inducible promoter, a constitutive promoter, and a tissue-specific promoter.

[0420] 35. The method of any one of embodiments 32-34, wherein the AAV vector further comprises a polyadenylation signal sequence.

[0421] 36. The method of any one of embodiments 32-35, wherein the mammal is a human.

[0422] 37. The method of any one of embodiments 32-36, wherein the mammal has been identified or diagnosed as having an acoustic neuroma.

[0423] 38. The method of any one of embodiments 32-36, wherein the mammal has been identified or diagnosed as having a vestibular schwannoma.

[0424] 39. The method of any one of embodiments 32-36, wherein the mammal has been identified or diagnosed as having neurofibromatosis type 2.

[0425] 40. A method as described in any of embodiments 32-39, wherein the AAV vector comprises a nucleic acid sequence encoding the following polypeptides: a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide.

[0426] 41. A method as described in any of embodiments 32-40, wherein the AAV vector comprises a nucleic acid sequence encoding the following polypeptide: a polypeptide comprising an antigen-binding antibody fragment operably linked to a signal peptide.

[0427] 42. The method of any one of embodiments 1-41, wherein the antibody comprises an Fc region comprising one or more amino acid substitutions that shorten the half-life of the antibody in a mammal compared to a control antibody; or

[0428] The antigen-binding antibody fragment of the antibody has a reduced in vivo half-life compared to a control antigen-binding antibody fragment.

[0429] 43. A method comprising introducing into the inner ear of a mammal a therapeutically effective amount of an adeno-associated viral (AAV) vector comprising a nucleotide sequence encoding a soluble vascular endothelial growth factor (VEGF) receptor operably linked to a signal peptide.

[0430] 44. A method for increasing the level of a soluble vascular endothelial growth factor (VEGF) receptor in the inner ear of a mammal in need thereof, the method comprising:

[0431] introducing into the inner ear of the mammal a therapeutically effective amount of an AAV vector comprising a nucleotide sequence encoding soluble VEGF operably linked to a signal peptide;

[0432] wherein said introducing results in an increase in the level of said soluble VEGF receptor in the inner ear of said mammal.

[0433] 45. The method of embodiment 43 or 44, wherein the soluble VEGF receptor comprises a portion of the extracellular region of VEGF receptor-1 (VEGFR-1).

[0434] 46. ​​A method as described in embodiment 45, wherein the portion of the extracellular region of VEGFR-1 includes a continuous sequence from wild-type human VEGFR-1.

[0435] 47. A method as described in embodiment 46, wherein the portion of the extracellular region of VEGFR-1 includes one or more immunoglobulin-like domains in the extracellular region of wild-type human VEGFR-1.

[0436] 48. The method of embodiment 45, wherein the portion of the extracellular region of VEGFR-1 comprises a sequence that is at least 90% identical to a contiguous sequence from wild-type human VEGFR-1.

[0437] 49. The method of embodiment 43 or 44, wherein the soluble VEGF receptor comprises a portion of the extracellular region of VEGF receptor-2 (VEGFR-2).

[0438] 50. A method as described in embodiment 49, wherein the portion of the extracellular region of VEGFR-2 includes a continuous sequence from wild-type human VEGFR-2.

[0439] 51. A method as described in embodiment 50, wherein the portion of the extracellular region of VEGFR-2 includes one or more immunoglobulin-like domains in the extracellular region of wild-type human VEGFR-2.

[0440] 52. A method as described in embodiment 49, wherein the portion of the extracellular region of VEGFR-2 includes a sequence that is at least 90% identical to a continuous sequence from wild-type human VEGFR-2.

[0441] 53. The method of embodiment 43 or 44, wherein the soluble VEGF receptor comprises a portion of the extracellular region of VEGFR-1 and a portion of the extracellular region of VEGFR-2.

[0442] 54. The method of embodiment 53, wherein:

[0443] The part of the extracellular region of VEGFR-1 includes one or more immunoglobulin-like domains from the extracellular region of wild-type human VEGFR-1; and

[0444] The part of the extracellular region of VEGFR-2 includes one or more immunoglobulin-like domains from the extracellular region of wild-type human VEGFR-2.

[0445] 55. The method of embodiment 54, wherein the soluble VEGF receptor is aflibercept.

[0446] 56. The method of embodiment 43 or 44, wherein the soluble VEGF receptor comprises a portion of the extracellular region of VEGF receptor-3 (VEGFR-3).

[0447] 57. A method as described in embodiment 56, wherein the portion of the extracellular region of VEGFR-3 includes a continuous sequence from wild-type human VEGFR-3.

[0448] 58. A method as described in embodiment 57, wherein the portion of the extracellular region of VEGFR-3 includes one or more immunoglobulin-like domains in the extracellular region of wild-type human VEGFR-3.

[0449] 59. The method of embodiment 56, wherein the portion of the extracellular region of VEGFR-3 comprises a sequence that is at least 90% identical to a contiguous sequence from wild-type human VEGFR-3.

[0450] 60. The method of any one of embodiments 43-59, wherein the soluble VEGF receptor comprises an Fc domain.

[0451] 61. The method of embodiment 60, wherein the Fc domain is an IgG1 Fc domain.

[0452] 62. The method of embodiment 61, wherein the IgG1 Fc domain is a human wild-type IgG1 Fc domain.

[0453] 63. The method of any one of embodiments 43-62, wherein the soluble VEGF receptor reduces the ability of VEGF to bind to one or more of VEGFR-1, VEGFR-2, and VEGFR-3.

[0454] 64. The method of any one of embodiments 43-63, wherein the AAV vector further comprises one or both of a promoter and a Kozak sequence operably linked to a sequence encoding the soluble VEGF receptor.

[0455] 65. The method of embodiment 64, wherein the AAV vector comprises a promoter selected from the group consisting of an inducible promoter, a constitutive promoter, and a tissue-specific promoter.

[0456] 66. The method of any one of embodiments 43-65, wherein the AAV vector further comprises a polyadenylation signal sequence.

[0457] 67. The method of any one of embodiments 43-66, wherein the mammal is a human.

[0458] 68. The method of any one of embodiments 43-67, wherein the mammal has been identified as having an inner ear disorder.

[0459] 69. The method of any one of embodiments 43-67, wherein the mammal has been diagnosed with an inner ear disorder.

[0460] 70. A method for treating an inner ear disorder in a mammal in need thereof, the method comprising:

[0461] introducing into the inner ear of the mammal a therapeutically effective amount of an AAV vector comprising a nucleotide sequence encoding a soluble vascular endothelial growth factor (VEGF) receptor operably linked to a signal peptide;

[0462] wherein said introducing results in said inner ear disorder being treated in said mammal.

[0463] 71. A method as described in embodiment 70, wherein the AAV vector further comprises one or both of a promoter and a Kozak sequence operably linked to the sequence encoding the soluble VEGF receptor.

[0464] 72. The method of embodiment 71, wherein the AAV vector comprises a promoter selected from the group consisting of an inducible promoter, a constitutive promoter, and a tissue-specific promoter.

[0465] 73. The method of any one of embodiments 70-72, wherein the AAV vector further comprises a polyadenylation signal sequence.

[0466] 74. The method of any one of embodiments 70-73, wherein the mammal is a human.

[0467] 75. The method of any one of embodiments 70-74, wherein the mammal has been identified as having an inner ear disorder.

[0468] 76. The method of any one of embodiments 70-74, wherein the mammal has been diagnosed with an inner ear disorder.

[0469] 77. A method of reducing VEGF activity in the inner ear of a mammal in need thereof, the method comprising:

[0470] introducing into the inner ear of the mammal a therapeutically effective amount of an AAV vector comprising a nucleotide sequence encoding a soluble vascular endothelial growth factor (VEGF) receptor operably linked to a signal peptide;

[0471] wherein said introducing results in a decrease in said VEGF activity in the inner ear of said mammal.

[0472] 78. A method as described in embodiment 77, wherein the AAV vector further comprises one or both of a promoter and a Kozak sequence operably linked to the sequence encoding the soluble VEGF receptor.

[0473] 79. The method of embodiment 78, wherein the AAV vector comprises a promoter selected from the group consisting of an inducible promoter, a constitutive promoter, and a tissue-specific promoter.

[0474] 80. The method of any one of embodiments 77-79, wherein the AAV vector further comprises a polyadenylation signal sequence.

[0475] 81. The method of any one of embodiments 77-80, wherein the mammal is a human.

[0476] 82. The method of any one of embodiments 77-81, wherein the mammal has been identified or diagnosed as having an acoustic neuroma.

[0477] 83. The method of any one of embodiments 77-81, wherein the mammal has been identified or diagnosed as having a vestibular schwannoma.

[0478] 84. The method of any one of embodiments 77-81, wherein the mammal has been identified or diagnosed as having neurofibromatosis type 2.

[0479] 85. A method of treating an acoustic neuroma, a vestibular schwannoma, or neurofibromatosis type 2 in the inner ear of a mammal, the method comprising:

[0480] introducing into the inner ear of the mammal a therapeutically effective amount of an AAV vector comprising a nucleotide sequence encoding a soluble vascular endothelial growth factor (VEGF) receptor operably linked to a signal peptide;

[0481] wherein said introducing results in treatment of an acoustic neuroma, a vestibular schwannoma or neurofibromatosis type II, respectively, in the inner ear of said mammal.

[0482] 86. A method as described in embodiment 85, wherein the AAV vector further comprises one or both of a promoter and a Kozak sequence operably linked to the sequence encoding the soluble VEGF receptor.

[0483] 87. The method of embodiment 86, wherein the AAV vector comprises a promoter selected from the group consisting of an inducible promoter, a constitutive promoter, and a tissue-specific promoter.

[0484] 88. The method of any one of embodiments 85-87, wherein the AAV vector further comprises a polyadenylation signal sequence.

[0485] 89. The method of any one of embodiments 85-88, wherein the mammal is a human.

[0486] 90. The method of any one of embodiments 85-89, wherein the mammal has been identified or diagnosed as having an acoustic neuroma.

[0487] 91. The method of any one of embodiments 85-89, wherein the mammal has been identified or diagnosed as having a vestibular schwannoma.

[0488] 92. The method of any one of embodiments 85-89, wherein the mammal has been identified or diagnosed as having neurofibromatosis type 2.

[0489] 93. The method of any one of embodiments 70-92, wherein the soluble VEGF receptor comprises a portion of the extracellular region of VEGF receptor-1 (VEGFR-1).

[0490] 94. A method as described in embodiment 93, wherein the portion of the extracellular region of VEGFR-1 includes a continuous sequence from wild-type human VEGFR-1.

[0491] 95. A method as described in embodiment 94, wherein the portion of the extracellular region of VEGFR-1 includes one or more immunoglobulin-like domains from the extracellular region of wild-type human VEGFR-1.

[0492] 96. A method as described in embodiment 93, wherein the portion of the extracellular region of VEGFR-1 includes a sequence that is at least 90% identical to a continuous sequence from wild-type human VEGFR-1.

[0493] 97. The method of any one of embodiments 70-92, wherein the soluble VEGF receptor comprises a portion of the extracellular region of VEGF receptor-2 (VEGFR-2).

[0494] 98. A method as described in embodiment 97, wherein the portion of the extracellular region of VEGFR-2 includes a continuous sequence from wild-type human VEGFR-2.

[0495] 99. A method as described in embodiment 98, wherein the portion of the extracellular region of VEGFR-2 includes one or more immunoglobulin-like domains from the extracellular region of wild-type human VEGFR-2.

[0496] 100. The method of embodiment 97, wherein the portion of the extracellular region of VEGFR-2 comprises a sequence that is at least 90% identical to a contiguous sequence from wild-type human VEGFR-2.

[0497] 101. The method of any one of embodiments 70-92, wherein the soluble VEGF receptor comprises a portion of the extracellular region of VEGFR-1 and a portion of the extracellular region of VEGFR-2.

[0498] 102. The method of embodiment 101, wherein:

[0499] The part of the extracellular region of VEGFR-1 includes one or more immunoglobulin-like domains from the extracellular region of wild-type human VEGFR-1; and

[0500] The part of the extracellular region of VEGFR-2 includes one or more immunoglobulin-like domains from the extracellular region of wild-type human VEGFR-2.

[0501] 103. The method of embodiment 102, wherein the soluble VEGF receptor is aflibercept.

[0502] 104. The method of any one of embodiments 70-92, wherein the soluble VEGF receptor comprises a portion of the extracellular region of VEGF receptor-3 (VEGFR-3).

[0503] 105. The method of embodiment 104, wherein the portion of the extracellular region of VEGFR-3 comprises a continuous sequence from wild-type human VEGFR-3.

[0504] 106. A method as described in embodiment 105, wherein the portion of the extracellular region of VEGFR-3 includes one or more immunoglobulin-like domains in the extracellular region of wild-type human VEGFR-3.

[0505] 107. The method of embodiment 104, wherein the portion of the extracellular region of VEGFR-3 comprises a sequence that is at least 90% identical to a contiguous sequence from wild-type human VEGFR-3.

[0506] 108. The method of any one of embodiments 70-107, wherein the soluble VEGF receptor comprises an Fc domain.

[0507] 109. The method of embodiment 108, wherein the Fc domain is an IgG1 Fc domain.

[0508] 110. The method of embodiment 109, wherein the IgG1 Fc domain is a human wild-type IgG1 Fc domain.

[0509] 111. The method of any one of embodiments 70-110, wherein the soluble VEGF receptor reduces the ability of VEGF to bind to one or more of VEGFR-1, VEGFR-2, and VEGFR-3.

[0510] 112. The method of any one of embodiments 43-111, wherein the AAV vector further comprises a secretory sequence.

Claims

1. A method comprising introducing a therapeutically effective amount of an adeno-associated virus (AAV) vector into the inner ear of a mammal, wherein the adeno-associated virus (AAV) vector comprises a nucleotide sequence encoding the following polypeptide: (a) a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide; or (b) A polypeptide comprising an antigen-binding antibody fragment operably linked to a signal peptide.

2. A method for increasing the level of an antibody or antigen-binding antibody fragment in the inner ear of a mammal in need thereof, the method comprising: A therapeutically effective amount of an AAV vector is introduced into the inner ear of the mammal, wherein the AAV vector comprises a nucleotide sequence encoding the following polypeptide: (a) a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide; or (b) a polypeptide comprising an antigen-binding antibody fragment linked to a signal peptide; wherein said introducing results in increased levels of said antibody or antigen-binding antibody fragment in the inner ear of said mammal.

3. The method of claim 1 or 2, wherein the antibody or the antigen-binding antibody fragment specifically binds to vascular endothelial growth factor (VEGF).

4. The method of claim 3, wherein the antibody or antigen-binding antibody fragment reduces VEGF activity.

5. The method of any one of claims 1-4, wherein the AAV vector further comprises one or both of a promoter and a Kozak sequence operably linked to a sequence encoding the antibody or the antigen-binding antibody fragment.

6. The method of claim 5, wherein the AAV vector comprises a promoter selected from the group consisting of an inducible promoter, a constitutive promoter, and a tissue-specific promoter.

7. The method of any one of claims 1-6, wherein the AAV vector further comprises a polyadenylation signal sequence.

8. The method of any one of claims 1-7, wherein the mammal is a human.

9. The method of any one of claims 1-8, wherein the mammal has been identified as having an inner ear disorder.

10. The method of any one of claims 1-8, wherein the mammal has been diagnosed with an inner ear disorder.